

# CITATION REPORT

List of articles citing

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

DOI: 10.1001/jama.275.2.134

JAMA - Journal of the American Medical Association, 1996, 275, 134-141.

**Source:** <https://exaly.com/paper-pdf/82999281/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 841 | Clinical perspectives on the management of community-acquired pneumonia. <b>1996</b> , 25, 205-11  |      | 5         |
| 840 | Community-acquired pneumonia. <b>1996</b> , 334, 861; author reply 862-3   |      | 1         |
| 839 | Prognosis and decisions in pneumonia. <b>1997</b> , 336, 288-9   |      | 21        |
| 838 | Treatment of acute biliary pancreatitis. <b>1997</b> , 336, 286-7  |      | 41        |
| 837 | The Hospital Discharge Decision for Patients With Community-Acquired Pneumonia. <b>1997</b> , 157, 47  |      | 56        |
| 836 | Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial. <b>1997</b> , 132, 1086-92  |      | 23        |
| 835 | Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. <b>1997</b> , 53, 700-25 |      | 53        |
| 834 | A prediction rule to identify low-risk patients with community-acquired pneumonia. <b>1997</b> , 336, 243-50   |      | 4391      |
| 833 | Risk Factors for 30-Day Mortality in Elderly Patients With Lower Respiratory Tract Infection. <b>1997</b> , 157, 2190  |      | 45        |
| 832 | Does This Patient Have Community-Acquired Pneumonia?. <i>JAMA - Journal of the American Medical Association</i> , <b>1997</b> , 278, 1440  | 27.4 | 209       |
| 831 | The Impact of Alcohol-Related Diagnoses on Pneumonia Outcomes. <b>1997</b> , 157, 1446   |      | 76        |
| 830 | A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia. <b>1997</b> , 58, 903-916                              |      | 9         |
| 829 | Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. <b>1997</b> , 12, 423-30  |      | 91        |
| 828 | Community-acquired pneumonia. <b>1998</b> , 352, 1295-302  |      | 126       |
| 827 | Efficacy and tolerability of twice-daily ciprofloxacin 750 mg in the treatment of patients with acute exacerbations of chronic bronchitis and pneumonia. <b>1998</b> , 20, 141-55    |      | 8         |
| 826 | Patient selection in outpatient parenteral antimicrobial therapy. <b>1998</b> , 12, 835-47, v-vi   |      | 18        |
| 825 | Practical considerations and guidelines for the management of community-acquired pneumonia. <b>1998</b> , 55, 31-45  |      | 45        |

|     |   |      |     |
|-----|---|------|-----|
| 824 | Community-acquired pneumonia: epidemiology, etiology, treatment. <b>1998</b> , 12, 723-40   |      | 66  |
| 823 | The role of atypical pathogens: <i>Mycoplasma pneumoniae</i> , <i>Chlamydia pneumoniae</i> , and <i>Legionella pneumophila</i> in respiratory infection. <b>1998</b> , 12, 569-92, vii                                      |      | 94  |
| 822 | Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. <b>1998</b> , 26, 811-38   |      | 717 |
| 821 | Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. <b>1998</b> , 10, 35-46   |      | 10  |
| 820 | Clinical and economic outcomes of empiric parenteral antibiotic therapy for pneumonia: a retrospective study of 1,032 hospitalized patients. <b>1998</b> , 10, 369-74   |      | 3   |
| 819 | Empirical therapy for nonhospitalized patients with community-acquired pneumonia. Study Group of General Practitioners. <b>1998</b> , 11, 73-8  |      | 11  |
| 818 | Geriatric respiratory medicine. <i>Chest</i> , <b>1998</b> , 114, 1704-33   | 5.3  | 129 |
| 817 | The Evolution of Antimicrobial Resistance in Respiratory Pathogens in Canada: What are the Clinical Consequences?. <b>1998</b> , 9, 10E-15E   |      | 1   |
| 816 | Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against <i>Streptococcus pneumoniae</i> in an in vitro model of infection. <b>1999</b> , 43, 672-7   |      | 188 |
| 815 | A Six-Year Epidemiologic Review of Pneumonia in Department of Veterans Affairs Facilities. <b>1999</b> , 164, 293-297   |      | 2   |
| 814 | Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. <i>Chest</i> , <b>1999</b> , 116, 157-65   | 5.3  | 49  |
| 813 | Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. <b>1999</b> , 159, 2562-72  |      | 332 |
| 812 | Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. <b>1999</b> , 179 Suppl 2, S342-52 |      | 112 |
| 811 | Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia. <i>Journal of Infection</i> , <b>1999</b> , 39, 171-8  | 18.9 | 10  |
| 810 | Recent advances in the management of pleural sepsis: what is the evidence?. <b>1999</b> , 4, 207-12   |      | 1   |
| 809 | Validation of the pneumonia severity index. Importance of study-specific recalibration. <b>1999</b> , 14, 333-40  |      | 35  |
| 808 | Antibiotic usage and the incidence of resistance. <i>Clinical Microbiology and Infection</i> , <b>1999</b> , 5 Suppl 4, S12-S16   | 5.3  | 5   |
| 807 | Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. <b>1999</b> , 6, 1243-8   |      | 81  |

|     |  |     |
|-----|--|-----|
| 806 | Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. <b>1999</b> , 25, 198-206                                    | 70  |
| 805 | Microbial aetiology of community-acquired pneumonia in hospitalised patients. <b>1999</b> , 18, 777-82   | 43  |
| 804 | New directions for future studies of community-acquired pneumonia: optimizing impact on patient care. <b>1999</b> , 18, 847-51                           | 19  |
| 803 | Treatment of Community-Acquired Pneumonia Requiring Admission to a Hospital Ward. <b>1999</b> , 1, 455-457   | 2   |
| 802 | A Critical Pathway for the Treatment of Community-Acquired Pneumonia. <b>1999</b> , 58, 273-275  | 3   |
| 801 | Pneumococcal vaccination in the elderly: an underused option?. <b>1999</b> , 12, 19-25   | 2   |
| 800 | Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. <b>1999</b> , 21, 103-17  | 41  |
| 799 | Infections in patients with diabetes mellitus. <b>1999</b> , 341, 1906-12  | 710 |
| 798 | Antibiotic therapy for community-acquired pneumonia. <b>1999</b> , 20, 589-98, ix  | 9   |
| 797 | Severe community-acquired pneumonia. <b>1999</b> , 20, 575-87  | 65  |
| 796 | Use of prognostic scoring and outcome assessment tools in the admission decision for community-acquired pneumonia. <b>1999</b> , 20, 521-9, viii         | 17  |
| 795 | Pneumonia in the elderly. <b>1999</b> , 20, 563-73   | 48  |
| 794 | A prognostic rule for elderly patients admitted with community-acquired pneumonia. <b>1999</b> , 106, 20-8   | 128 |
| 793 | Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. <b>1999</b> , 14, 370-375                           | 1   |
| 792 | The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. <i>Chest</i> , <b>1999</b> , 116, 1278-83                                  | 64  |
| 791 | Pneumonia da Comunidade em Portugal Continental â€” Internamentos Hospitalares em 1997. <b>1999</b> , 5, 477-485   | 2   |
| 790 | [What is the cost of inappropriate admission of pneumonia patients?]. <b>1999</b> , 35, 312-6  | 11  |
| 789 | [Community-acquired pneumonia referred for hospital management. Its epidemiology and the diagnostic and therapeutic approaches]. <b>1999</b> , 35, 27-32 | 7   |

|     |  |      |      |
|-----|--|------|------|
| 788 | Influence of Comorbidity and Severity on the Clinical Outcome of Bacteremic Pneumococcal Pneumonia Treated with Eactam Monotherapy. <b>1999</b> , 11, 241-247  |      | 1    |
| 787 | A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. <i>Chest</i> , <b>1999</b> , 116, 974-83   | 5.3  | 31   |
| 786 | Implementation of admission decision support for community-acquired pneumonia. <i>Chest</i> , <b>2000</b> , 117, 1368-77   | 5.3  | 59   |
| 785 | Severity assessment in community-acquired pneumonia. <b>2000</b> , 16, 1193-201  |      | 34   |
| 784 | Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. <b>2000</b> , 90, 223-9   |      | 400  |
| 783 | Management strategies for community acquired pneumonia. <b>2000</b> , 24, 279-88   |      | 1    |
| 782 | Anaerobic Infections of the Lung. <b>2000</b> , 2, 238-244   |      | 10   |
| 781 | Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections. <b>2000</b> , 2, 399-408  |      | 9    |
| 780 | An update on community-acquired pneumonia in adults. <b>2000</b> , 26, 283-93  |      | 2    |
| 779 | Seven-year study of bacteraemic pneumonia in a single institution. <b>2000</b> , 19, 926-31  |      | 16   |
| 778 | Treatment of Respiratory Infections with Quinolones. <b>2000</b> , 255-284   |      | 1    |
| 777 | Development of a best-practice model at a university hospital to increase efficiency in the management of patients with community-acquired pneumonia. <b>2000</b> , 57 Suppl 3, S6-9   |      | 5    |
| 776 | The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. <b>2000</b> , 55, 83-5   |      | 8    |
| 775 | In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. <b>2000</b> , 31 Suppl 2, S16-23  |      | 66   |
| 774 | Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. <b>2000</b> , 30, 520-8   |      | 221  |
| 773 | Severity prediction rules in community acquired pneumonia: a validation study. <b>2000</b> , 55, 219-23  |      | 122  |
| 772 | A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 283, 749-55 | 27.4 | 451  |
| 771 | Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. <b>2000</b> , 31, 347-82   |      | 1226 |

|     |  |      |
|-----|--|------|
| 770 | Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. <b>2000</b> , 44, 1796-802  | 54   |
| 769 | <i>Pseudomonas aeruginosa</i> community-acquired pneumonia in previously healthy adults: case report and review of the literature. <b>2000</b> , 31, 1349-56   | 98   |
| 768 | <i>Haemophilus influenzae</i> pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. <b>2000</b> , 30, 461-5  | 30   |
| 767 | Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. <b>2000</b> , 182, 840-7   | 143  |
| 766 | Clarithromycin in the management of community-acquired pneumonia. <b>2000</b> , 22, 281-94; discussion 265   | 22   |
| 765 | Pneumopathies communautaires d'origine virale en ranimation chez l'adulte immunocomptent. <b>2000</b> , 9, 523-533   |      |
| 764 | A review of clinical trials with fluoroquinolones with an emphasis on new agents. <b>2000</b> , 9, 383-413   | 19   |
| 763 | Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. <b>2000</b> , 31, 383-421 | 527  |
| 762 | Diagnosis of pneumonia and monitoring of infection eradication. <b>2000</b> , 60, 1289-302   | 12   |
| 761 | Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. <b>2001</b> , 18, 19-27   | 32   |
| 760 | The clinical impact of macrolide resistance in pneumococcal respiratory infections. <b>2001</b> , 18 Suppl 1, S33-8  | 11   |
| 759 | Worldwide guidelines for respiratory tract infections: community-acquired pneumonia. <b>2001</b> , 18 Suppl 1, S39-44  | 12   |
| 758 | [Bilateral submandibular infection by the parotiditis virus]. <b>2001</b> , 117, 78-9  | 1    |
| 757 | Recomendaciones ALAT sobre la neumonã adquirida en la comunidad. <b>2001</b> , 37, 340-348   | 10   |
| 756 | Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. <b>2001</b> , 163, 1730-54  | 1706 |
| 755 | Nonresolving pneumonia and mimics of pneumonia. <i>Medical Clinics of North America</i> , <b>2001</b> , 85, 1511-30, xi  | 7 24 |
| 754 | The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. <b>2001</b> , 95, 78-82   | 136  |
| 753 | Traitement antibiotique des pneumonies communautaires de l'adulte â rapport des nouvelles molcules ; place des traitements de durẽ abrge ; donnẽs pharmaco-õconomiques. <b>2001</b> , 31, 174-180  | 1    |

|     |  |   |     |
|-----|--|---|-----|
| 752 | Nosologie des infections des voies aériennes basses. <b>2001</b> , 31, 609-613   |   |     |
| 751 | Pneumonia in the elderly. <i>Medical Clinics of North America</i> , <b>2001</b> , 85, 1441-59  | 7 | 39  |
| 750 | The role of atypical pathogens in community-acquired pneumonia. <i>Medical Clinics of North America</i> , <b>2001</b> , 85, 1349-65, vii   | 7 | 20  |
| 749 | Defining severe community-acquired pneumonia. <i>Medical Clinics of North America</i> , <b>2001</b> , 85, 1413-25  | 7 | 14  |
| 748 | [Community-acquired pneumonia requiring hospital admission. A comparison of the clinical management, resource use and prognosis by different medical specialties]. <b>2001</b> , 201, 65-8 |   | 2   |
| 747 | [Community acquired pneumonia in patients older than 60 years. Incidence of atypical agents and clinical-radiological progression]. <b>2001</b> , 117, 441-5                               |   | 7   |
| 746 | Evaluación de la etiología y del abordaje terapéutico de la neumonía adquirida en la comunidad. <b>2001</b> , 116, 179-181   |   | 2   |
| 745 | Infections in diabetes. <b>2001</b> , 15, 407-21, viii   |   | 132 |
| 744 | [Prospective study of 221 community acquired pneumonias followed up in an outpatient clinic. Etiology and clinical-radiological progression]. <b>2001</b> , 116, 161-6                     |   | 6   |
| 743 | [Community acquired pneumonias followed in ambulatory care]. <b>2001</b> , 117, 79   |   |     |
| 742 | Laboratory diagnosis of community-acquired lower respiratory tract infection. <b>2001</b> , 15, 1025-45  |   | 7   |
| 741 | Neumonía en el anciano. <b>2001</b> , 117, 454-456   |   | 4   |
| 740 | Cartas al Editor. <b>2001</b> , 117, 79  |   |     |
| 739 | Economic evaluations of adult pneumococcal vaccination strategies. <b>2001</b> , 1, 47-58  |   | 11  |
| 738 | Pre- and in-hospital management of community-acquired pneumonia in southern France, 1998-99. <b>2001</b> , 20, 770-8   |   | 9   |
| 737 | Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. <b>2001</b> , 10, 213-37   |   | 13  |
| 736 | Acute pneumonia and systemic lupus erythematosus. <b>2001</b> , 14, 88-93  |   |     |
| 735 | Estudo de casos hospitalizados por pneumonia comunitária no período de um ano. <b>2001</b> , 27, 243-248   |   | 2   |

|     |   |     |     |
|-----|---|-----|-----|
| 734 | Community-acquired pneumonia. A prospective outpatient study. <b>2001</b> , 80, 75-87   |     | 79  |
| 733 | Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms. <b>2001</b> , 13, 402-6 |     | 2   |
| 732 | Quality indicators for the management of pneumonia in vulnerable elders. <b>2001</b> , 135, 736-43  |     | 18  |
| 731 | Initial risk class and length of hospital stay in community-acquired pneumonia. <b>2001</b> , 18, 151-6   |     | 37  |
| 730 | Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged > or = 75 yrs. <b>2001</b> , 17, 200-5   |     | 51  |
| 729 | Appropriate microbiological testing in community-acquired pneumonia. <i>Chest</i> , <b>2001</b> , 119, 5-7  | 5.3 | 9   |
| 728 | Get a Handle on Resistance Before It Gets a Handle on You. <b>2001</b> , 94, 891-892  |     | 1   |
| 727 | Pneumonia no idoso. <b>2001</b> , 7, 465-473  |     |     |
| 726 | A pneumonia adquirida na comunidade. O internamento hospitalar: quem, quando e onde?. <b>2001</b> , 7, 378-388  |     |     |
| 725 | Community-acquired pneumonia: the evolving challenge. <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 30-38   | 9.5 | 11  |
| 724 | Relationship of Penicillin Resistance to Mortality in Pneumococcal Pneumonia. <b>2001</b> , 3, 9-12   |     | 6   |
| 723 | Hospitalization decision for ambulatory patients with community-acquired pneumonia: a prospective study with general practitioners in France. <b>2001</b> , 29, 320-5   |     | 8   |
| 722 | Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 589-96  | 9.5 | 185 |
| 721 | Fatal <i>Roseomonas gilardii</i> bacteremia in a patient with refractory blast crisis of chronic myeloid leukemia. <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 573-5  | 9.5 | 27  |
| 720 | What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia?. <b>2001</b> , 16, 599-605  |     | 41  |
| 719 | Community-acquired pneumonia in patients requiring hospitalization. <b>2001</b> , 6, 259-64   |     | 31  |
| 718 | Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. <b>2001</b> , 6, 323-30  |     | 19  |
| 717 | Clinical policy for the management and risk stratification of community-acquired pneumonia in adults in the emergency department. <b>2001</b> , 38, 107-13  |     | 25  |



|     |  |     |     |
|-----|--|-----|-----|
| 716 | An emergency department-based randomized trial of nonbronchoscopic bronchoalveolar lavage for early pathogen identification in severe community-acquired pneumonia. <b>2001</b> , 38, 357-63                           |     | 14  |
| 715 | Mixed bacteremic pneumonia by <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> . <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 571  | 9.5 |     |
| 714 | Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against <i>Streptococcus pneumoniae</i> . <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 572-573      | 9.5 | 2   |
| 713 | A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. <b>2001</b> , 21, 89S-94S               |     | 10  |
| 712 | Community-acquired pneumonia: the evolving challenge. <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 30-38  | 9.5 | 21  |
| 711 | Diabetes and the risk of infection-related mortality in the U.S. <b>2001</b> , 24, 1044-9  |     | 181 |
| 710 | Severity assessment of lower respiratory tract infection in elderly patients in primary care. <b>2001</b> , 161, 2709-13   |     | 33  |
| 709 | Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired <i>Streptococcus pneumoniae</i> pneumonia. <b>2001</b> , 161, 848-50                                     |     | 86  |
| 708 | Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. <i>Chest</i> , <b>2001</b> , 120, 185-92   | 5.3 | 33  |
| 707 | Evaluation of a rapid immunochromatographic test for detection of <i>Streptococcus pneumoniae</i> antigen in urine samples from adults with community-acquired pneumonia. <b>2001</b> , 39, 3495-8                     |     | 197 |
| 706 | Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. <b>2001</b> , 35, 1180-5  |     | 37  |
| 705 | Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). <b>2001</b> , 45, 3104-8  |     | 62  |
| 704 | Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. <b>2001</b> , 33, 158-65                   |     | 664 |
| 703 | Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant <i>Streptococcus pneumoniae</i> : a randomized study of amoxicillin-clavulanate and ceftriaxone. <b>2001</b> , 7, 85-96 |     | 47  |
| 702 | <i>Mycoplasma pneumoniae</i> Pneumonia. <b>2002</b> , 487-500  |     |     |
| 701 | Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. <b>2002</b> , 36, 3s-8s   |     | 56  |
| 700 | Treatment of community-acquired lower respiratory tract infections in adults. <b>2002</b> , 36, 40s-53s  |     | 19  |
| 699 | Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers. <b>2002</b> , 46, 917-21   |     | 25  |

|     |   |      |     |
|-----|---|------|-----|
| 698 | Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. <b>2002</b> , 162, 1059-64  |      | 245 |
| 697 | Pneumococcal Pneumonia. <b>2002</b> , 427-454   |      | 1   |
| 696 | Use of ??-Lactam/??-Lactamase Inhibitor Combinations to Treat Community-Acquired Respiratory Tract Infections. <b>2002</b> , 11, S20-S26  |      |     |
| 695 | Clinical Experience With Newer Quinolones for Community-Acquired Pneumonia. <b>2002</b> , 527-533   |      |     |
| 694 | Polymerase Chain Reaction Techniques in the Diagnosis of Pneumonia. <b>2002</b> , 45-54   |      |     |
| 693 | Management of patients with community-acquired pneumonia treated in hospital in Sweden. <b>2002</b> , 34, 887-92  |      | 24  |
| 692 | Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant <i>Streptococcus pneumoniae</i> . <b>2002</b> , 34 Suppl 1, S17-26                                   |      | 68  |
| 691 | Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model. <b>2002</b> , 14, 591-6                                     |      | 3   |
| 690 | Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 2561-8 | 27.4 | 248 |
| 689 | Tumor necrosis factor-alpha-converting enzyme: its role in community-acquired pneumonia. <b>2002</b> , 186, 1790-6  |      | 20  |
| 688 | Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. <b>2002</b> , 35, 11-7   |      | 53  |
| 687 | The pulmonary physician in critical care . 3: critical care management of community acquired pneumonia. <b>2002</b> , 57, 267-71  |      | 21  |
| 686 | Epidemiology of Community-Acquired Pneumonia. <b>2002</b> , 13-27   |      |     |
| 685 | International Respiratory Tract Infection Guidelines. <b>2002</b> , 11, S3-S11  |      |     |
| 684 | Withholding antibiotic treatment in pneumonia patients with dementia: a quantitative observational study. <b>2002</b> , 162, 1753-60  |      | 90  |
| 683 | Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (Consensur). <b>2002</b> , 14 Suppl 4, 1-22                      |      | 9   |
| 682 | An intervention to improve antibiotic delivery and sputum procurement in patients hospitalized with community-acquired pneumonia. <i>Chest</i> , <b>2002</b> , 122, 913-9   | 5.3  | 17  |
| 681 | The application of molecular techniques to diagnosis of viral respiratory tract infections. <b>2002</b> , 13, 177-185   |      | 8   |

|     |  |     |
|-----|--|-----|
| 680 | A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. <b>2002</b> , 34, 1076-83   | 64  |
| 679 | Clinical practice. Management of community-acquired pneumonia. <b>2002</b> , 347, 2039-45  | 126 |
| 678 | Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. <b>2002</b> , 19, 61-6   | 14  |
| 677 | Penicillin resistant <i>Streptococcus pneumoniae</i> isolated from infected children in Athens, Greece: resistance patterns, serotypes and penicillin-binding protein 2B mutation characterization by PCR. <b>2002</b> , 20, 147-9   | 0   |
| 676 | The efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate 2000/125 mg, twice daily, versus oral amoxicillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. <b>2002</b> , 20, 119-29                             | 23  |
| 675 | [Community-acquired pneumonia in the elderly: prognostic factors]. <b>2002</b> , 38, 67-71   | 9   |
| 674 | Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. <b>2002</b> , 20, 513-28  | 19  |
| 673 | Differential V gene expression detected in the immune response to <i>Streptococcus pneumoniae</i> capsular polysaccharide between elderly and young adults. <b>2002</b> , 21, 19-24  | 2   |
| 672 | Respiratory rate measurement in adults--how reliable is it?. <b>2002</b> , 96, 31-3  | 42  |
| 671 | A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. <b>2002</b> , 24, 1292-308   | 66  |
| 670 | Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. <b>2002</b> , 24, 1915-36 | 55  |
| 669 | A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia. <b>2002</b> , 24, 605-15  | 23  |
| 668 | Intérêt d'un score de gravité des pneumonies communautaires : application du score de Fine aux pneumonies admises au centre hospitalier d'Annecy. <b>2002</b> , 32, 19-27  |     |
| 667 | Efficacité comparée de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aiguës communautaires de l'adulte hospitalisé avec facteur de risque. <b>2002</b> , 32, 369-381  | 19  |
| 666 | [When to admit a patient with community-acquired pneumonia]. <b>2002</b> , 38, 549-51  | 2   |
| 665 | Antimicrobial therapy for community-acquired pneumonia in adults. <b>2002</b> , 6, 82-7  | 1   |
| 664 | Aspectos relevantes da interface entre diabetes mellitus e infecção. <b>2002</b> , 46, 221-229   | 8   |
| 663 | 3: Community-acquired pneumonia. <b>2002</b> , 176, 341-7  | 31  |

|     |   |     |     |
|-----|---|-----|-----|
| 662 | The emerging role of atypical pathogens in community-acquired pneumonia. <b>2002</b> , 22, 2S-11S; discussion 30S-32S   |     | 20  |
| 661 | [Bacterial pneumonias]. <b>2002</b> , 43, 375-82, 384-95; quiz 396-7  |     | 0   |
| 660 | Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia--a case-control study. <b>2002</b> , 2, 28  |     | 46  |
| 659 | Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. <i>Clinical Microbiology and Infection</i> , <b>2002</b> , 8 Suppl 2, 1-11      | 9.5 | 38  |
| 658 | A predictive model for the management of community-acquired pneumonia. <b>2003</b> , 31, 3-8  |     | 14  |
| 657 | A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults. <b>2003</b> , 31, 308-17                                      |     | 15  |
| 656 | [Community-acquired and nosocomial pneumonia]. <b>2003</b> , 44 Suppl 1, S44-58   |     | 0   |
| 655 | Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive <i>Streptococcus pneumoniae</i> isolates from France. <b>2003</b> , 22, 561-5 |     | 7   |
| 654 | The pathophysiological significance of prognostic factors for fatal outcome in lower respiratory tract infections. <b>2003</b> , 8, 53-7  |     | 3   |
| 653 | Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. <i>Clinical Microbiology and Infection</i> , <b>2003</b> , 9, 949-54         | 9.5 | 30  |
| 652 | Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. <b>2003</b> , 21, 395-420   |     | 16  |
| 651 | [Community-acquired pneumonia requiring hospitalization in immunocompetent elderly patients: clinical features, prognostic factors and treatment]. <b>2003</b> , 39, 333-40     |     | 13  |
| 650 | Community-acquired pneumonia in the elderly. <b>2003</b> , 19, 729-48   |     | 32  |
| 649 | International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. <b>2003</b> , 63, 181-205   |     | 21  |
| 648 | Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. <b>2003</b> , 22, 96-103              |     | 102 |
| 647 | Community-acquired pneumonia. <b>2003</b> , 362, 1991-2001  |     | 361 |
| 646 | Factors associated with hospitalization costs for patients with community-acquired pneumonia. <b>2003</b> , 25, 593-610   |     | 20  |
| 645 | Delirium in the elderly resulting from azithromycin therapy. <b>2003</b> , 59, 509-11   |     | 17  |

|     |  |         |
|-----|--|---------|
| 644 | Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. <b>2003</b> , 97, 625-33  | 30      |
| 643 | Connective tissue responses in acute community-acquired pneumonia. <b>2003</b> , 97, 660-6   | 2       |
| 642 | Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. <b>2003</b> , 97, 1134-42  | 25      |
| 641 | Utilidad de una nueva t cnica r pida de detecci n de ant geno neumoc tico en el diagn stico de la neumon  comunitaria. <b>2003</b> , 203, 521-525  | 1       |
| 640 | Optimizing treatment outcomes in severe community-acquired pneumonia. <b>2003</b> , 2, 39-54   | 13      |
| 639 | Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia. <b>2003</b> , 188, 769-76   | 36      |
| 638 | Factors associated with death among adults . <b>2003</b> , 36, 413-21  | 39      |
| 637 | Chlamydia species as a cause of community-acquired pneumonia in Canada. <b>2003</b> , 21, 779-84   | 49      |
| 636 | Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. <b>2003</b> , 58, 377-82                                     | 1759    |
| 635 | Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. <b>2003</b> , 41, 495-7   | 130     |
| 634 | What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia?. <b>2003</b> , 36, 396-8  | 35      |
| 633 | Pneumonia: still the old man's friend?. <b>2003</b> , 163, 317-23  | 162     |
| 632 | Community-acquired pneumonia in the elderly: Spanish multicentre study. <b>2003</b> , 21, 294-302  | 86      |
| 631 | Evaluation of a PCR assay for detection of <i>Streptococcus pneumoniae</i> in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. <b>2003</b> , 41, 63-6 | 91      |
| 630 | Mortality during hospitalisation for pneumonia in Alberta, Canada, is associated with physician volume. <b>2003</b> , 22, 148-55   | 34      |
| 629 | Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. <b>2003</b> , 21, 135-43  | 76      |
| 628 | Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. <i>Chest</i> , <b>2003</b> , 123, 1503-11           | 5:3 127 |
| 627 | [Pneumonia in the adult population in continental Portugal -- incidence and mortality in hospitalized patients from 1998 to 2000]. <b>2003</b> , 9, 187-94                                 | 12      |

|     |  |     |     |
|-----|--|-----|-----|
| 626 | Chronic bronchitis in an elderly population. <b>2003</b> , 32, 636-42  |     | 37  |
| 625 | Linezolid vs Vancomycin *. <i>Chest</i> , <b>2003</b> , 124, 1789-1797   | 5:3 | 524 |
| 624 | Microbiological testing and outcome of patients with severe community-acquired pneumonia. <i>Chest</i> , <b>2003</b> , 123, 174-80   | 5:3 | 138 |
| 623 | Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). <b>2003</b> , 58, 686-9   |     | 242 |
| 622 | [CAPNet--network of competence for community acquired pneumonia: structures and aims]. <b>2003</b> , 57, 34-41   |     | 3   |
| 621 | Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2003. A 73-year-old woman with pneumonia and progressive respiratory failure. <b>2003</b> , 348, 1902-12   |     | 5   |
| 620 | [Portuguese Respiratory Society guidelines for the management of community-acquired pneumonia in immunocompetent adults]. <b>2003</b> , 9, 435-61  |     | 1   |
| 619 | Severe community-acquired pneumonia: what's in a name?. <b>2003</b> , 16, 153-9  |     | 24  |
| 618 | Utility of Gram Stain and Sputum Culture in the Management of Community-Acquired Pneumonia. <b>2003</b> , 10, 1-5  |     | 2   |
| 617 | Variation in management of community-acquired pneumonia requiring admission to Alberta, Canada hospitals. <b>2003</b> , 130, 41-51   |     | 27  |
| 616 | Update: Management of Parapneumonic Effusions. <b>2003</b> , 10, 336-342   |     | 4   |
| 615 | Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. <b>2003</b> , 31, 1367-72  |     | 79  |
| 614 | The admission of patients with pneumonia directly from the Emergency Department to Hospital in the Home. <b>2003</b> , 12, 12-15   |     | 3   |
| 613 | Testing strategies in the initial management of patients with community-acquired pneumonia. <b>2003</b> , 138, 109-18  |     | 152 |
| 612 | Management of community-acquired pneumonia at a tertiary care medical center in Lebanon. <b>2003</b> , 60, 934-8   |     | 3   |
| 611 | Prevalence of <i>Streptococcus pneumoniae</i> resistance to penicillin in two hospitals of Caxias do Sul. <b>2003</b> , 29, 15-20  |     |     |
| 610 | Mycoplasma disease and acute chest syndrome in sickle cell disease. <b>2003</b> , 112, 87-95   |     | 58  |
| 609 | An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers. <b>2003</b> , 7, 62-8 |     | 2   |

|     |   |          |
|-----|---|----------|
| 608 | Management of Community-Acquired Pneumonia in One Hospital Compared with a National Benchmark Database. <b>2003</b> , 38, 351-356   |          |
| 607 | [Bacteremic pneumococcal pneumonia in 45 immunocompromised hospitalized adults]. <b>2004</b> , 132, 588-94  | 3        |
| 606 | [Incidence of pneumococcal pneumonias in hospital settings in the autonomous Community of Valencia throughout the 1995-2001 period. Spain]. <b>2004</b> , 78, 517-25  | 2        |
| 605 | Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic <i>Streptococcus pneumoniae</i> pneumonia in adults. <b>2004</b> , 11, 589-93                            | 74       |
| 604 | Blood cultures for community-acquired pneumonia: piecing together a mosaic for doing less. <b>2004</b> , 169, 327-8   | 11       |
| 603 | Pulmonary complications in diabetes mellitus: the role of glycemic control. <b>2004</b> , 3, 455-8  | 27       |
| 602 | Severe acute respiratory syndrome: correlation between clinical outcome and radiologic features. <b>2004</b> , 233, 579-85  | 37       |
| 601 | Vascular dysfunction in sleep apnea: a reversible link to cardiovascular disease?. <b>2004</b> , 169, 328-9   | 13       |
| 600 | Sepsis. <b>2004</b> ,   | 1        |
| 599 | Cefepime versus ceftazidime for treatment of pneumonia. <b>2004</b> , 32, 84-93   | 7        |
| 598 | Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. <b>2004</b> , 189, 450-8 | 63       |
| 597 | Peak expiratory flow (PEF) monitoring. <b>2004</b> , 59, 913-4  | 4        |
| 596 | Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. <b>2004</b> , 24, 779-85  | 114      |
| 595 | Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 1955-60  | 27.4 596 |
| 594 | Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. <b>2004</b> , 38, 1570-8             | 81       |
| 593 | Unravelling salt transport in cystic fibrosis. <b>2004</b> , 59, 916-7  |          |
| 592 | Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. <b>2004</b> , 24, 644-8   | 13       |
| 591 | Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. <b>2004</b> , 27, 752-7   | 202      |

|     |  |      |     |
|-----|--|------|-----|
| 590 | What happens to patients with respiratory disease when they fly?. <b>2004</b> , 59, 919-20   |      | 5   |
| 589 | Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. <b>2004</b> , 48, 3323-31 |      | 32  |
| 588 | Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. <b>2004</b> , 164, 502-8  |      | 149 |
| 587 | Macrolide-Resistant <i>Streptococcus pneumoniae</i> in Community-Acquired Pneumonia: Clinical and Microbiological Outcomes for Patients Treated with Levofloxacin. <b>2004</b> , 38, S24-S33   |      | 4   |
| 586 | Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. <i>Chest</i> , <b>2004</b> , 125, 1888-901   | 5:3  | 84  |
| 585 | Identifying failure of empirical treatment for pneumonia: vigilance and common sense. <b>2004</b> , 59, 918-9  |      |     |
| 584 | Tuberculosis and anti-TNF-alpha treatment. <b>2004</b> , 59, 921   |      | 14  |
| 583 | Single-dose azithromycin for respiratory tract infections. <b>2004</b> , 38, 433-9   |      | 8   |
| 582 | Difficult bacteria, antibiotic resistance and transmissibility in cystic fibrosis. <b>2004</b> , 59, 914-5   |      | 13  |
| 581 | Cumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal Bacteremia. <b>2004</b> , 38, S34-S42  |      | 10  |
| 580 | Management of Multiple Drug-Resistant Infections. <b>2004</b> ,  |      | 1   |
| 579 | Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies. <i>Clinical Microbiology and Infection</i> , <b>2004</b> , 10, 27-36  | 9:5  | 8   |
| 578 | Management of community-acquired pneumonia in persons with spinal cord injury. <b>2004</b> , 42, 450-8   |      | 14  |
| 577 | [Competence network "community acquired pneumonia" (CAPNETZ). A first interim report]. <b>2004</b> , 45, 393-401   |      | 13  |
| 576 | [Treatment of severe pneumonia--community-acquired and "early onset" nosocomial]. <b>2004</b> , 99, 362-71   |      | 0   |
| 575 | The septic shock associated HSPA1B1267 polymorphism influences production of HSPA1A and HSPA1B. <b>2004</b> , 30, 1761-7   |      | 37  |
| 574 | CAPNETZ-community-acquired pneumonia competence network. <b>2004</b> , 32, 234-8   |      | 64  |
| 573 | Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. <i>Journal of Infection</i> , <b>2004</b> , 49, 115-25  | 18:9 | 15  |



|     |   |         |
|-----|---|---------|
| 572 | Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. <b>2004</b> , 37, 204-9  | 41      |
| 571 | Chronic ethanol ingestion and the risk of acute lung injury: a role for glutathione availability?. <b>2004</b> , 33, 191-7  | 79      |
| 570 | Streptococcus pneumoniae: epidemiology and patterns of resistance. <b>2004</b> , 117 Suppl 3A, 3S-15S   | 29      |
| 569 | Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. <b>2004</b> , 117 Suppl 3A, 39S-50S   | 41      |
| 568 | Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns. <b>2004</b> , 24, 531-51   | 3       |
| 567 | Diagnostic test for etiologic agents of community-acquired pneumonia. <b>2004</b> , 18, 809-27  | 28      |
| 566 | [Outpatient care or hospitalization? A crucial decision in the treatment of community-acquired pneumonia]. <b>2004</b> , 22, 61-3   | 3       |
| 565 | Actualizaci3n de las recomendaciones ALAT sobre la neumon3a adquirida en la comunidad. <b>2004</b> , 40, 364-374  | 78      |
| 564 | Recomendaciones para el tratamiento de la neumon3a intrahospitalaria grave. <b>2004</b> , 28, 262-278   | 5       |
| 563 | [Validation of the Pneumonia Severity Index for hospitalizing patients with community-acquired pneumonia]. <b>2004</b> , 122, 481-6   | 3       |
| 562 | Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae. <b>2004</b> , 18, 963-74; x-xi   | 9       |
| 561 | Nonresponses and treatment failures with conventional empiric regimens in patients with community-acquired pneumonia. <b>2004</b> , 18, 883-97  | 6       |
| 560 | [Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia]. <b>2004</b> , 40, 364-74  | 4       |
| 559 | Recommendations for the Treatment of Severe Nosocomial Pneumonia. <b>2004</b> , 40, 518-533   | 1       |
| 558 | Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience. <b>2004</b> , 24, 485-90  | 31      |
| 557 | Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). <b>2004</b> , 24, 479-84 | 31      |
| 556 | Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000. <b>2004</b> , 8, 362-73  | 9       |
| 555 | Clinical importance of cystic fibrosis-related diabetes. <i>Journal of Cystic Fibrosis</i> , <b>2004</b> , 3, 209-22  | 4.1 101 |

|     |  |    |
|-----|--|----|
| 554 | Azithromycin for acute lower respiratory tract infections. <b>2004</b> , CD001954  | 7  |
| 553 | Epidemiology and etiology of community-acquired pneumonia. <b>2004</b> , 18, 761-76, vii   | 64 |
| 552 | Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?. <b>2004</b> , 38 Suppl 4, S346-9          | 22 |
| 551 | [Recommendations for the treatment of severe nosocomial pneumonia]. <b>2004</b> , 40, 518-33   | 4  |
| 550 | Recomendaciones para el tratamiento de la neumonía intrahospitalaria grave. <b>2004</b> , 22, 471-485  |    |
| 549 | Lung abscesses and jaundice due to prolonged Escherichia coli bacteremia associated with pyelonephritis: a forgotten entity. <b>2004</b> , 15, 321-322       |    |
| 548 | [The computer-assisted management programs for antibiotic therapies in connection with an application in geriatrics]. <b>2004</b> , 52, 589-96               | 2  |
| 547 | Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia. <b>2004</b> , 65, 225-38                              | 6  |
| 546 | Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia. <b>2004</b> , 26, 294-303 | 15 |
| 545 | Diagnosis of infection in sepsis: an evidence-based review. <b>2004</b> , 32, S466-94  | 69 |
| 544 | New method of classifying infections in critically ill patients. <b>2004</b> , 32, 1510-26   | 59 |
| 543 | Pneumonia in the Elderly. <b>2004</b> , 11, 210-218  | 7  |
| 542 | Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. <b>2004</b> , 11, 433-42                            | 23 |
| 541 | Escherichia coli pneumonia enhances granulopoiesis and the mobilization of myeloid progenitor cells into the systemic circulation. <b>2004</b> , 32, 1740-6  | 37 |
| 540 | Community-acquired pneumonia: updates in assessment and management. <b>2004</b> , 27, 231-40   | 4  |
| 539 | Importance of severity of illness assessment in management of lower respiratory infections. <b>2004</b> , 17, 121-5  | 13 |
| 538 | Práticas actuais na abordagem hospitalar da pneumonia adquirida na comunidade em Portugal. Consenso de um painel de peritos. <b>2005</b> , 11, 243-282       | 1  |
| 537 | Are Blood Cultures Necessary in Community-Acquired Pneumonia?. <b>2005</b> , 12, 146-152   | 2  |

|     |   |     |    |
|-----|---|-----|----|
| 536 | Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia. <b>2005</b> , 11, 1-13  |     | 39 |
| 535 | Pneumonies communautaires graves de l'adulte. <b>2005</b> , 2, 1-18   |     |    |
| 534 | Do emergency department blood cultures change practice in patients with pneumonia?. <b>2005</b> , 46, 393-400   |     | 71 |
| 533 | Blood cultures for community-acquired pneumonia: can we hit the target without a shotgun?. <b>2005</b> , 46, 407-8  |     | 21 |
| 532 | Evidence-based emergency medicine/rational clinical examination abstract. Diagnosing pneumonia by medical history and physical examination. <b>2005</b> , 46, 465-7   |     | 10 |
| 531 | Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival. <b>2005</b> , 53, 1108-16  |     | 50 |
| 530 | Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant <i>Streptococcus pneumoniae</i> in community-acquired pneumonia. <i>International Journal of Clinical Practice</i> , <b>2005</b> , 59, 1253-9 | 2.9 | 15 |
| 529 | B-type natriuretic peptide for risk stratification in community-acquired pneumonia. <b>2005</b> , 258, 391-3  |     | 44 |
| 528 | Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. <b>2005</b> , 20, 230-8   |     | 32 |
| 527 | [Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)]. <b>2005</b> , 41, 272-89  |     | 48 |
| 526 | Pacientes ingresados por neumonía adquirida en la comunidad: estudio comparativo en función de la especialidad del servicio médico responsable. <b>2005</b> , 41, 300-306   |     | 11 |
| 525 | Neumonía: predecir la mala evolución. <b>2005</b> , 41, 475-477   |     | 3  |
| 524 | Guías para el manejo de la neumonía comunitaria del adulto que precisa ingreso en el hospital. <b>2005</b> , 29, 21-62  |     | 5  |
| 523 | [Community-acquired pneumonia]. <b>2005</b> , 2, 8-16   |     |    |
| 522 | Role of beta-lactam agents in the treatment of community-acquired pneumonia. <b>2005</b> , 24, 83-99  |     | 23 |
| 521 | Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. <b>2005</b> , 24, 190-5  |     | 98 |
| 520 | New Resident Fellow Announced. <b>2005</b> , 46, 467  |     |    |
| 519 | Manejo de la neumonía del adulto adquirida en la comunidad: Resumen del consenso nacional. <b>2005</b> , 133, 953   |     | 0  |

|     |  |         |
|-----|--|---------|
| 518 | Does Initial Choice of Antimicrobial Therapy Affect Length of Stay for Patients with Complicated Intra-abdominal Infections?. <b>2005</b> , 71, 816-820  | 6       |
| 517 | Epidemiolog  de la neumon  del adulto adquirida en la comunidad. <b>2005</b> , 21, 73  | 0       |
| 516 | Epidemiolog  de la neumon  del adulto adquirida en la comunidad. <b>2005</b> , 22, s11   | 2       |
| 515 | Neumon  grave del adulto adquirida en la comunidad. <b>2005</b> , 22, s46  |         |
| 514 | Etiolog  de la neumon  adquirida en la comunidad en el adulto inmunocompetente. <b>2005</b> , 21, 81   |         |
| 513 | Evaluaci  de la gravedad en la neumon  del adulto adquirida en la comunidad. <b>2005</b> , 21, 103   |         |
| 512 | Neumon  grave del adulto adquirida en la comunidad. <b>2005</b> , 21, 111  |         |
| 511 | Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. <b>2005</b> , 41, 1709-16 | 187     |
| 510 | Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. <b>2005</b> , 43, 3221-6   | 75      |
| 509 | Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. <b>2005</b> , 165, 1992-2000  | 79      |
| 508 | Does guideline adherence for empiric antibiotic therapy reduce mortality in community-acquired pneumonia?. <b>2005</b> , 172, 655-6  | 22      |
| 507 | Bigger may be better: targeted beta2-agonist therapy. <b>2005</b> , 172, 656-7   |         |
| 506 | [S3-guideline on ambulant acquired pneumonia and deep airway infections]. <b>2005</b> , 59, 612-64   | 31      |
| 505 | U.K. Controlled trial of intrapleural streptokinase for pleural infection. <b>2005</b> , 352, 865-74   | 581     |
| 504 | Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin. <b>2005</b> , 51, 186-92                              | 13      |
| 503 | Severe Acute Respiratory Syndrome (SARS): A Brief Review With Exploration of the Outcomes, Prognostic Factors and Sequelae. <b>2005</b> , 1, 85-92   | 2       |
| 502 | Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens. <b>2005</b> , 1, 265-271  |         |
| 501 | Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. <i>Chest</i> , <b>2005</b> , 128, 3854-62                             | 5.3 811 |

|     |  |    |     |
|-----|--|----|-----|
| 500 | Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. <b>2005</b> , 17, 636-42                |    | 9   |
| 499 | The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. <i>Chest</i> , <b>2005</b> , 128, 940-6   | 53 | 49  |
| 498 | A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. <b>2005</b> , 27, 1251-9  |    | 32  |
| 497 | Project protect: pneumococcal vaccination in Washington State nursing homes. <b>2005</b> , 6, 91-6   |    | 7   |
| 496 | Etiology of community-acquired pneumonia. <b>2005</b> , 26, 47-55  |    | 40  |
| 495 | Antimicrobial treatment of community-acquired pneumonia. <b>2005</b> , 26, 65-73   |    | 10  |
| 494 | Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. <b>2005</b> , 56, 575-82  |    | 42  |
| 493 | A multiplex PCR for detection of <i>Mycoplasma pneumoniae</i> , <i>Chlamydia pneumoniae</i> , <i>Legionella pneumophila</i> , and <i>Bordetella pertussis</i> in clinical specimens. <b>2005</b> , 19, 314-22  |    | 45  |
| 492 | [Antibiotic in general and current practice in lower respiratory tract infections in adults and children. Arguments]. <b>2005</b> , 35, 635-94   |    | 5   |
| 491 | Antimicrobial susceptibilities of potential bacterial pathogens in adults with acute respiratory tract infections Prospective Epidemiological Network Investigating Community-acquired Infection SurveilLance In Nagasaki (PENICILLIN) Study. <b>2005</b> , 51, 271-80 |    | 8   |
| 490 | Pneumonies communautaires graves de l'adulte. <b>2005</b> , 2, 141-166   |    |     |
| 489 | [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults]. <b>2005</b> , 53, 503-10  |    | 10  |
| 488 | Etiology and outcomes of veterans with spinal cord injury and disorders hospitalized with community-acquired pneumonia. <b>2005</b> , 86, 262-7  |    | 12  |
| 487 | Arterial carbon dioxide tension on admission as a marker of in-hospital mortality in community-acquired pneumonia. <b>2005</b> , 118, 145-50   |    | 41  |
| 486 | Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. <b>2005</b> , 118, 384-92  |    | 231 |
| 485 | Antimicrobial treatment of lower respiratory tract infections in the hospital setting. <b>2005</b> , 118 Suppl 7A, 29S-38S   |    | 41  |
| 484 | Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). <b>2005</b> , 41, 272-289   |    | 41  |
| 483 | [Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area]. <b>2005</b> , 41, 300-6  |    | 1   |

|     |  |     |
|-----|--|-----|
| 482 | [Predicting poor outcome of pneumonia]. <b>2005</b> , 41, 475-7  | 1   |
| 481 | Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by <i>Streptococcus pneumoniae</i> , including penicillin-resistant strains. <b>2005</b> , 25, 110-9                                  | 10  |
| 480 | Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for <i>Streptococcus pneumoniae</i> . <b>2005</b> , 26, 120-5 | 19  |
| 479 | Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. <b>2005</b> , 60, 672-8   | 107 |
| 478 | Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. <b>2005</b> , 142, 165-72   | 165 |
| 477 | Neumonías comunitarias graves del adulto. <b>2006</b> , 32, 1-20   |     |
| 476 | Antibiothérapie aux urgences. <b>2006</b> , 15, 514-522  | 2   |
| 475 | Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. <b>2006</b> , 42, 73-81  | 64  |
| 474 | Alcohol abuse in the critically ill patient. <b>2006</b> , 368, 2231-42  | 72  |
| 473 | Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. <b>2006</b> , 174, 84-93   | 702 |
| 472 | [Pneumonia awareness year, 2004: scientific impact through publications in Archivos de Bronconeumología]. <b>2006</b> , 42, 541-52   | 3   |
| 471 | Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review. <b>2006</b> , 10, 136-47   | 7   |
| 470 | Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. <b>2006</b> , 54, 267-75   | 7   |
| 469 | [Assessment, triage, and follow-up of a patient with: acute CAP COPD]. <b>2006</b> , 36, 734-83  |     |
| 468 | [Managing lower respiratory tract infections in immunocompetent patients. Definitions, epidemiology, and diagnostic features]. <b>2006</b> , 36, 784-802   | 3   |
| 467 | Prise en charge des infections des voies respiratoires basses de l'adulte immunocompetent. Texte long. <b>2006</b> , 36, S231-S261   | 1   |
| 466 | Predictors of mortality for lower respiratory infections in nursing home residents with dementia were validated transnationally. <b>2006</b> , 59, 970-9   | 47  |
| 465 | Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. <b>2006</b> , 100, 577-85   | 13  |

|     |  |     |     |
|-----|--|-----|-----|
| 464 | Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients. <b>2006</b> , 100, 1342-8  |     | 8   |
| 463 | [Ambulatory management of community acquired pneumonia in the elderly]. <b>2006</b> , 134, 1568-75   |     | 1   |
| 462 | Manejo de la neumonía comunitaria del adulto en el Servicio de Salud Viña del Mar-Quillota. Abril - Septiembre de 2003. <b>2006</b> , 22, 13   |     |     |
| 461 | [Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients]. <b>2006</b> , 134, 1357-66  |     | 2   |
| 460 | Enfermedades infecciosas de los pulmones. <b>2006</b> , 222-336  |     | 1   |
| 459 | CAP Management Guidelines. <b>2006</b> , 31, 43-53   |     | 2   |
| 458 | Outcomes of outpatient visits for acute respiratory illness in veterans with spinal cord injuries and disorders. <b>2006</b> , 85, 718-26  |     | 20  |
| 457 | Physical Medicine and Rehabilitation Board Review. <b>2006</b> , 85, 726   |     |     |
| 456 | Eighteenth Annual Legislative Update. <b>2006</b> , 31, 12-38  |     |     |
| 455 | Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by <i>Streptococcus pneumoniae</i> . <i>Chest</i> , <b>2006</b> , 130, 807-14 | 5.3 | 27  |
| 454 | Antibiotiques chez le sujet âgé. <b>2006</b> , 1, 1-8  |     |     |
| 453 | Sleep in critically ill chemically paralyzed patients requiring mechanical ventilation. <i>Chest</i> , <b>2006</b> , 129, 1468-77  | 5.3 | 89  |
| 452 | Clinical implications and treatment of multiresistant <i>Streptococcus pneumoniae</i> pneumonia. <i>Clinical Microbiology and Infection</i> , <b>2006</b> , 12 Suppl 3, 31-41            | 9.5 | 49  |
| 451 | Impact of antibiotic restrictions: the physician's perspective. <i>Clinical Microbiology and Infection</i> , <b>2006</b> , 12 Suppl 5, 3-9   | 9.5 | 7   |
| 450 | Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , <b>2006</b> , 12, 1097-104              | 9.5 | 27  |
| 449 | Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. <b>2006</b> , 21, 745-52                               |     | 29  |
| 448 | A validation and potential modification of the pneumonia severity index in elderly patients with community-acquired pneumonia. <b>2006</b> , 54, 1212-9                                  |     | 31  |
| 447 | Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. <b>2006</b> , 259, 410-7  |     | 112 |

|     |  |     |     |
|-----|--|-----|-----|
| 446 | Detection of pneumolysin in human urine using an immunosensor on screen-printed carbon electrodes. <b>2006</b> , 113, 1005-1011  |     | 14  |
| 445 | Blood cultures do not change management in hospitalized patients with community-acquired pneumonia. <b>2006</b> , 13, 740-5  |     | 38  |
| 444 | Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. <b>2006</b> , 25, 159-66   |     | 34  |
| 443 | Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients. <b>2006</b> , 25, 369-74  |     | 42  |
| 442 | Community-acquired pneumonia and bacteremia caused by an unusual methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) strain with sequence type 36, staphylococcal cassette chromosome mec type IV and Panton-Valentine leukocidin genes. <b>2006</b> , 25, 604-6 |     | 12  |
| 441 | Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. <b>2006</b> , 12, 63-9  |     | 73  |
| 440 | Evaluation of the Binax NOW <i>Streptococcus pneumoniae</i> urinary antigen assay in intensive care patients hospitalized for pneumonia. <b>2006</b> , 32, 1766-72   |     | 40  |
| 439 | [Community acquired pneumonia CAP]. <b>2006</b> , 118, 153-75  |     | 1   |
| 438 | 2004: Año de la Neumonía. Consecuencias e impacto científico en Archivos de Bronconeumología. <b>2006</b> , 42, 541-552  |     | 5   |
| 437 | Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. <i>Chest</i> , <b>2006</b> , 129, 1219-25  | 5-3 | 118 |
| 436 | Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. <i>Chest</i> , <b>2006</b> , 130, 11-5  | 5-3 | 112 |
| 435 | Adverse Events in Patients With Community-Acquired Pneumonia at an Academic Tertiary Emergency Department. <b>2006</b> , 14, 350-359   |     | 1   |
| 434 | Pneumonia in the Elderly. <b>2006</b> , 2, 75-87   |     | 1   |
| 433 | Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. <b>2006</b> , 27, 1217-22  |     | 36  |
| 432 | Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter?. <b>2006</b> , 42, 224-33   |     | 75  |
| 431 | Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. <b>2006</b> , 13, 1092-7   |     | 37  |
| 430 | The clinical relevance of penicillin-resistant <i>Streptococcus pneumoniae</i> : a new perspective. <b>2006</b> , 42, 798-800  |     | 14  |
| 429 | The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. <b>2006</b> , 42, 788-97  |     | 91  |



|     |   |       |
|-----|---|-------|
| 428 | Parapneumonic effusions and empyema. <b>2006</b> , 3, 75-80   | 272   |
| 427 | Statin treatment and reduced risk of pneumonia in patients with diabetes. <b>2006</b> , 61, 957-61  | 97    |
| 426 | Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia. <b>2006</b> , 28, 816-23  | 49    |
| 425 | Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. <b>2006</b> , 43, 860-8   | 159   |
| 424 | Obesity and Diabetes. <b>2006</b> ,   | 4     |
| 423 | COPD is associated with increased mortality in patients with community-acquired pneumonia. <b>2006</b> , 28, 346-51   | 191   |
| 422 | Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant <i>Streptococcus pneumoniae</i> . <b>2006</b> , 57, 536-45                   | 16    |
| 421 | Unplayed Melodies: Javanese Gamelan and the Genesis of Music Theory:Unplayed Melodies: Javanese Gamelan and the Genesis of Music Theory. <b>2007</b> , 29, 247-253  |       |
| 420 | Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. <b>2007</b> , 335, 982  | 197   |
| 419 | Effects of systemic steroids in patients with severe community-acquired pneumonia. <b>2007</b> , 30, 951-6  | 1144  |
| 418 | Association of serotypes of <i>Streptococcus pneumoniae</i> with disease severity and outcome in adults: an international study. <b>2007</b> , 45, 46-51  | 125   |
| 417 | Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia. <b>2007</b> , 45, 1326-31   | 7     |
| 416 | Optimal Treatment of Severe Community-Acquired Pneumonia. <b>2007</b> , 3, 233-239  |       |
| 415 | Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health. <b>2007</b> , 62 Suppl 1, 1-46 | 36    |
| 414 | Increased hospital morbidity among trauma patients with diabetes mellitus compared with age- and injury severity score-matched control subjects. <b>2007</b> , 142, 613-8   | 40    |
| 413 | Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. <i>Chest</i> , <b>2007</b> , 132, 515-22  | 53 85 |
| 412 | Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. <b>2007</b> , 35, 2509-14  | 85    |
| 411 | Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. <b>2007</b> , 25, 235-9   | 25    |

|     |   |      |      |
|-----|---|------|------|
| 410 | Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. <b>2007</b> , 35, 1493-8  |      | 166  |
| 409 | Necrotizing Pneumonia and Pulmonary Gangrene. <b>2007</b> , 14, 166-170   |      | 1    |
| 408 | Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. <i>Chest</i> , <b>2007</b> , 131, 779-787                     | 5.3  | 78   |
| 407 | Community-acquired pneumonia: what is relevant and what is not?. <b>2007</b> , 13, 177-85   |      | 10   |
| 406 | Community-Acquired Pneumonia in Alcoholic Patients. <b>2007</b> , 14, 258-264   |      |      |
| 405 | A case series of macrolide treatment failures in community acquired pneumonia. <b>2007</b> , 19, 536-45   |      | 23   |
| 404 | Characteristics of low-risk patients hospitalized with community-acquired pneumonia. <b>2007</b> , 18, 209-14   |      | 10   |
| 403 | Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by <i>Streptococcus pneumoniae</i> : a Monte Carlo simulation analysis. <b>2007</b> , 29, 2685-9 |      | 10   |
| 402 | Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. <b>2007</b> , 78, 392-7                                |      | 31   |
| 401 | [Evaluating care in community acquired pneumonia]. <b>2007</b> , 24, 183-96   |      | 0    |
| 400 | Type 2 diabetes and pneumonia outcomes: a population-based cohort study. <b>2007</b> , 30, 2251-7   |      | 161  |
| 399 | Pulmonary and cardiac infections in athletes. <b>2007</b> , 26, 361-82  |      | 3    |
| 398 | Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. <b>2007</b> , 44 Suppl 2, S27-72                                 |      | 4193 |
| 397 | [Community-acquired respiratory infections in non-immunocompromised adults]. <b>2007</b> , 24, 381-6  |      | 1    |
| 396 | The role of the macrophage in lung disease mediated by bacteria. <b>2007</b> , 33, 493-505  |      | 76   |
| 395 | [Predictive value of history and physical examination for the diagnosis of community-acquired pneumonia in adults: a literature review]. <b>2007</b> , 135, 517-28  |      | 4    |
| 394 | Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility. <b>2007</b> , 11, 322-6  |      | 8    |
| 393 | Approaches to estimate the population-based incidence of community acquired pneumonia. <i>Journal of Infection</i> , <b>2007</b> , 55, 233-9  | 18.9 | 57   |

|     |   |        |
|-----|---|--------|
| 392 | Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. <b>2007</b> , 24, 1168-71   | 45     |
| 391 | Statines ter preventie van pneumonie. <b>2008</b> , 51, 195-197   | 2      |
| 390 | Dood. <b>2008</b> , 51, 197-197   |        |
| 389 | Prior outpatient antibiotic use as predictor for microbial aetiology of community-acquired pneumonia: hospital-based study. <b>2008</b> , 64, 405-10  | 16     |
| 388 | The impact of pre-existing heart failure on pneumonia prognosis: population-based cohort study. <b>2008</b> , 23, 1407-13   | 34     |
| 387 | Pneumonia in stroke patients with oropharyngeal dysphagia: a six-month follow-up study. <b>2008</b> , 29, 139-45  | 70     |
| 386 | The lineage-c-Kit+Sca-1+ cell response to Escherichia coli bacteremia in Balb/c mice. <b>2008</b> , 26, 1778-86   | 72     |
| 385 | Community-acquired pneumonia: the evolving challenge. <i>Clinical Microbiology and Infection</i> , <b>2008</b> , 7, 30-38   | 9.5    |
| 384 | Factors impacting on length of stay and mortality of community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , <b>2008</b> , 14, 322-9   | 9.5 65 |
| 383 | Respiratory infections unique to Asia. <b>2008</b> , 13, 937-49   | 17     |
| 382 | A novel vertebrate model of Staphylococcus aureus infection reveals phagocyte-dependent resistance of zebrafish to non-host specialized pathogens. <b>2008</b> , 10, 2312-25  | 146    |
| 381 | Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. <b>2008</b> , 264, 166-76   | 70     |
| 380 | The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. <b>2008</b> , 8, 222  | 66     |
| 379 | The patient with possible pneumonia. <b>2008</b> , 4, 14-19   | 1      |
| 378 | Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia. <b>2008</b> , 31, 3-11   | 32     |
| 377 | Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. <b>2008</b> , 31, 107-14 | 123    |
| 376 | Identification of selected respiratory pathogens in endodontic infections. <b>2008</b> , 106, 145-51  | 9      |
| 375 | Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. <b>2008</b> , 26, 1955-62  | 30     |

|     |   |         |
|-----|---|---------|
| 374 | Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. <b>2008</b> , 60, 59-64 | 15      |
| 373 | Toward a quantitative DNA-based definition of pneumococcal pneumonia: a comparison of <i>Streptococcus pneumoniae</i> target genes, with special reference to the Spn9802 fragment. <b>2008</b> , 60, 143-50                      | 56      |
| 372 | Quantitative detection of <i>Streptococcus pneumoniae</i> from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia. <b>2008</b> , 60, 255-61             | 52      |
| 371 | Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. <b>2008</b> , 61, 329-38  | 93      |
| 370 | [Molecular biology in the diagnosis of acute bacterial infection of the respiratory tract]. <b>2008</b> , 26 Suppl 9, 26-32   | 1       |
| 369 | Community-acquired pneumonia. <b>2008</b> , 371, 455-8  | 28      |
| 368 | Antibiotic timing and errors in diagnosing pneumonia. <b>2008</b> , 168, 351-6  | 119     |
| 367 | Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value. <b>2008</b> , 47 Suppl 3, S145-9  | 7       |
| 366 | Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. <b>2008</b> , 15, 1391-7  | 76      |
| 365 | Growth of <i>Streptococcus pneumoniae</i> on human glycoconjugates is dependent upon the sequential activity of bacterial exoglycosidases. <b>2008</b> , 190, 221-30  | 128     |
| 364 | Molecular diagnostics for detection of bacterial and viral pathogens in community-acquired pneumonia. <b>2008</b> , 47 Suppl 3, S123-6  | 57      |
| 363 | At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. <b>2008</b> , 46, 1131-8  | 38      |
| 362 | Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. <b>2008</b> , 31, 741-6  | 164     |
| 361 | Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study. <b>2008</b> , 63, 817-22   | 21      |
| 360 | Novel targets in the management of pneumonia. <b>2008</b> , 2, 387-400  | 6       |
| 359 | Early mortality in patients with community-acquired pneumonia: causes and risk factors. <b>2008</b> , 32, 733-9   | 83      |
| 358 | Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. <b>2008</b> , 63, 698-702  | 59      |
| 357 | A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. <i>Chest</i> , <b>2008</b> , 133, 610-7  | 5-3 157 |

|     |  |    |     |
|-----|--|----|-----|
| 356 | Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. <i>Chest</i> , <b>2008</b> , 133, 220-5   | 53 | 17  |
| 355 | Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. <b>2008</b> , 20 Suppl 1, 28-35  |    | 20  |
| 354 | Prediction of complicated lower respiratory tract infections in older patients with diabetes. <b>2008</b> , 58, 564-8  |    | 11  |
| 353 | Pneumonia. <b>2008</b> , 635-644   |    |     |
| 352 | Community-Acquired Pneumonia. 221-228  |    |     |
| 351 | Pneumonia: Considerations for the Critically Ill Patient. <b>2008</b> , 867-883  |    |     |
| 350 | Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial. <b>2008</b> , 12, 202-9 |    | 3   |
| 349 | Pneumonia estafilocócica adquirida na comunidade. <b>2008</b> , 34, 683-689  |    | 6   |
| 348 | Comorbidades e sinais de alerta da pneumonia adquirida na comunidade: análise de pacientes com mais de 50 anos. <b>2008</b> , 33,  |    |     |
| 347 | COMMUNITY-ACQUIRED PNEUMONIA. <b>2009</b> , 1081-1087  |    |     |
| 346 | Principle of Primacy of Patient Welfare. 115-153   |    |     |
| 345 | Factores pronósticos, evolución y mortalidad en el adulto inmunocompetente hospitalizado por neumonía neumocócica adquirida en la comunidad. <b>2009</b> , 137,  |    | 2   |
| 344 | Evaluación y manejo del adulto inmunocompetente hospitalizado por neumonía adquirida en la comunidad, en un hospital de baja complejidad, basado en la Guía Clínica Chilena. <b>2009</b> , 137,                      |    |     |
| 343 | Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. <b>2009</b> , 35, 574-601  |    | 37  |
| 342 | [Evaluation of Seeplex Pneumobacter multiplex PCR kit for the detection of respiratory bacterial pathogens in pediatric patients]. <b>2009</b> , 29, 307-13  |    | 9   |
| 341 | Usefulness of Procalcitonin in the Assessing the Severity of Community-Acquired Pneumonia Patient. <b>2009</b> , 67, 430   |    | 2   |
| 340 | Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. <b>2009</b> , 25, 2151-7   |    | 41  |
| 339 | Efficacy of pneumococcal vaccination in adults: a meta-analysis. <b>2009</b> , 180, 48-58  |    | 289 |

|     |  |        |
|-----|--|--------|
| 338 | Streptococcus pneumoniae DNA load in blood as a marker of infection in patients with community-acquired pneumonia. <b>2009</b> , 47, 3308-12   | 63     |
| 337 | Alcohol abuse and pulmonary disease. <b>2009</b> , 86, 1097-104  | 47     |
| 336 | Improving the simple, complicated and complex realities of community-acquired pneumonia. <b>2009</b> , 18, 93-8  | 8      |
| 335 | Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii. <i>Chest</i> , <b>2009</b> , 136, 1119-1127 5-3  | 31     |
| 334 | Severity assessment in community-acquired pneumonia: a review. <b>2009</b> , 102, 379-88   | 61     |
| 333 | [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. <b>2009</b> , 68, e1-68 | 89     |
| 332 | Community-acquired pneumonia: the U.S. perspective. <b>2009</b> , 30, 179-88   | 37     |
| 331 | Adjunctive therapy in community-acquired pneumonia. <b>2009</b> , 30, 146-53   | 13     |
| 330 | Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. <b>2009</b> , 64, 592-7   | 110    |
| 329 | Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. <b>2009</b> , 66, 469-80   | 30     |
| 328 | Identification of a pneumococcal glycosidase that modifies O-linked glycans. <b>2009</b> , 77, 1389-96   | 45     |
| 327 | Evaluation of a rapid immunochromatographic ODK0501 assay for detecting Streptococcus pneumoniae antigen in sputum samples from patients with lower respiratory tract infection. <b>2009</b> , 16, 672-8   | 11     |
| 326 | An evidence-based review of infectious diseases. <b>2009</b> , 30, 272-86  | 0      |
| 325 | Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review. <b>2009</b> , 4, 112-23   | 55     |
| 324 | Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. <b>2009</b> , 28, 971-6  | 10     |
| 323 | Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae. <b>2009</b> , 37, 358-64  | 22     |
| 322 | Inflammation markers in point-of-care testing (POCT). <b>2009</b> , 393, 1473-80   | 108    |
| 321 | Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. <i>BMC Pulmonary Medicine</i> , <b>2009</b> , 9, 44   | 3-5 42 |

|     |   |      |     |
|-----|---|------|-----|
| 320 | Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia?. <b>2009</b> , 14, 210-6   |      | 25  |
| 319 | Respiratory infections: a current and future threat. <b>2009</b> , 14, 651-5  |      | 11  |
| 318 | Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia. <b>2009</b> , 14, 1098-105  |      | 46  |
| 317 | Is quantitative PCR for the pneumolysin (ply) gene useful for detection of pneumococcal lower respiratory tract infection?. <i>Clinical Microbiology and Infection</i> , <b>2009</b> , 15, 565-70   | 9.5  | 18  |
| 316 | Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , <b>2009</b> , 15, 1026-32   | 9.5  | 40  |
| 315 | Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. <i>Clinical Microbiology and Infection</i> , <b>2009</b> , 15, 850-7  | 9.5  | 48  |
| 314 | A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. <i>Journal of Infection</i> , <b>2009</b> , 59, 83-9   | 18.9 | 63  |
| 313 | BTS guidelines for the management of community acquired pneumonia in adults: update 2009. <b>2009</b> , 64 Suppl 3, iii1-55   |      | 735 |
| 312 | Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. <b>2009</b> , 63, 52-61   |      | 75  |
| 311 | [Factors associated with prolonged hospital stay in community-acquired pneumonia]. <b>2009</b> , 27, 160-4  |      | 7   |
| 310 | Epidemiology of community-acquired pneumonia in older adults: a population-based study. <b>2009</b> , 103, 309-16   |      | 136 |
| 309 | Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by <i>Streptococcus pneumoniae</i> . <b>2009</b> , 27, 968-74   |      | 29  |
| 308 | Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S. <b>2009</b> , 37, 381-8  |      | 6   |
| 307 | Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant <i>Streptococcus pneumoniae</i> . <b>2009</b> , 13, 483-7 |      | 14  |
| 306 | Repeated pneumonia severity index measurement after admission increases its predictive value for mortality in severe community-acquired pneumonia. <b>2009</b> , 108, 219-23  |      | 6   |
| 305 | Severe community-acquired pneumonia. <b>2009</b> , 23, 503-20   |      | 55  |
| 304 | Cost-Effectiveness of B-Type Natriuretic Peptide in the Management of Dyspnea. <b>2009</b> , 16, 199-201  |      |     |
| 303 | Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. <i>Chest</i> , <b>2009</b> , 135, 165-172  | 5.3  | 32  |

|     |   |      |    |
|-----|---|------|----|
| 302 | Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia. <b>2009</b> , 16, 243-251   |      | 1  |
| 301 | Common medications that increase the risk for developing community-acquired pneumonia. <b>2010</b> , 23, 145-51   |      | 7  |
| 300 | Editorial from Guest Editor [Hot topic: Community-Acquired Pneumonia: A Review of Uncommon Topics (Guest Editor: Pedro J. Marcos)]. <b>2010</b> , 6, 149-149  |      |    |
| 299 | Inpatient care and microbial surveillance during year 2007-2008; retrospective evaluation of hospital-acquired pneumonia (HAP) in General Hospital Pulau Pinang, Malaysia. <b>2010</b> , 3, 27                      |      | 1  |
| 298 | Physical, Chemical and Bacteriological Study of Water from Rivers of Uttarakhand. <b>2010</b> , 32, 169-173   |      | 40 |
| 297 | Dysglycaemia and 90 day and 1 year risks of death or readmission in patients hospitalised for community-acquired pneumonia. <b>2010</b> , 53, 497-503   |      | 14 |
| 296 | Hyperglycemia in diabetics and non-diabetics: effect on the risk for and severity of pneumococcal pneumonia. <i>Journal of Infection</i> , <b>2010</b> , 60, 99-105   | 18.9 | 37 |
| 295 | Statins for community-acquired pneumonia: current state of the science. <b>2010</b> , 29, 143-52  |      | 37 |
| 294 | [Community-acquired pneumonia]. <b>2010</b> , 46 Suppl 7, 26-30   |      | 6  |
| 293 | Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-acquired pneumonia. <b>2010</b> , 25, 176.e7-13   |      | 42 |
| 292 | Influence of socioeconomic status on community-acquired pneumonia outcomes in elderly patients requiring hospitalization: a multicenter observational study. <b>2010</b> , 10, 421                                  |      | 11 |
| 291 | [Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)]. <b>2010</b> , 46, 543-58  |      | 78 |
| 290 | Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population. <i>Journal of Infection</i> , <b>2010</b> , 61, 458-64   | 18.9 | 39 |
| 289 | Prognostic indices for hospital mortality among Libyan diabetic patients. <b>2010</b> , 27, 392-395a  |      | 2  |
| 288 | Acute alcohol intoxication impairs the hematopoietic precursor cell response to pneumococcal pneumonia. <b>2010</b> , 34, 2035-43   |      | 22 |
| 287 | Receipt of influenza and pneumonia vaccinations: the dual disparity of rural minorities. <b>2010</b> , 58, 1896-902   |      | 14 |
| 286 | Usefulness of real-time PCR for <i>lytA</i> , <i>ply</i> , and <i>Spn9802</i> on plasma samples for the diagnosis of pneumococcal pneumonia. <i>Clinical Microbiology and Infection</i> , <b>2010</b> , 16, 1135-41 | 9.5  | 47 |
| 285 | <i>rpoA</i> is a useful gene for identification and classification of <i>Streptococcus pneumoniae</i> from the closely related viridans group streptococci. <b>2010</b> , 305, 58-64                                |      | 20 |



|     |   |     |
|-----|---|-----|
| 284 | Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. <b>2010</b> , 15, 918-22   | 68  |
| 283 | Neumonía aguda adquirida en la comunidad en adultos: Actualización de los lineamientos para el tratamiento antimicrobiano inicial basado en la evidencia local del Grupo de Trabajo de Sudamérica (ConsenSur II). <b>2010</b> , 27, | 1   |
| 282 | Respiratory Review of 2010: Pneumonia. <b>2010</b> , 68, 319  |     |
| 281 | Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. <b>2010</b> , 65, 77-81   | 72  |
| 280 | Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. <b>2010</b> , 51, 1042-9   | 117 |
| 279 | The influence of COPD on mortality and severity scoring in community-acquired pneumonia. <b>2010</b> , 79, 46-53  | 31  |
| 278 | Development and evaluation of an implementation strategy for the German guideline on community-acquired pneumonia. <b>2010</b> , 19, 498-502  | 12  |
| 277 | Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. <b>2010</b> , 36, 608-14   | 43  |
| 276 | Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. <b>2010</b> , 54, 4098-106   | 53  |
| 275 | Macrolides in Community-Acquired Pneumonia: The Importance of the Non-Antimicrobial Effect. <b>2010</b> , 6, 150-154  | 1   |
| 274 | Noninvasive Mechanical Ventilation in the Treatment of Community-Acquired Pneumonia. <b>2010</b> , 6, 167-170   |     |
| 273 | Immobilization of motile bacterial cells via dip-pen nanolithography. <b>2010</b> , 21, 235105  | 8   |
| 272 | Respiratory infections due to drug-resistant bacteria. <b>2010</b> , 24, 639-53   | 17  |
| 271 | Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. <b>2010</b> , 36, 197-204   | 71  |
| 270 | Community-Acquired Pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). <b>2010</b> , 46, 543-558  | 21  |
| 269 | Effect of oral Eblocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. <b>2010</b> , 14, R198  | 32  |
| 268 | [Efficacy of hospital at home (HaH) in the treatment of community-acquired pneumonia (CAP) with different degrees of severity]. <b>2010</b> , 135, 47-51  | 5   |
| 267 | Performance measure of urinary antigen in patients with Streptococcus pneumoniae bacteremia. <b>2010</b> , 67, 129-33   | 16  |

|     |  |     |     |
|-----|--|-----|-----|
| 266 | Statins in community acquired pneumonia: Evidence from experimental and clinical studies. <b>2010</b> , 104, 1081-91   |     | 63  |
| 265 | Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. <b>2010</b> , 104, 1736-43             |     | 23  |
| 264 | Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia. <b>2010</b> , 123, 556.e11-6   |     | 20  |
| 263 | Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. <b>2010</b> , 181, 975-82   |     | 199 |
| 262 | Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia. <b>2011</b> , 43, 448-55   |     | 13  |
| 261 | Community-acquired pneumonia: an unfinished battle. <i>Medical Clinics of North America</i> , <b>2011</b> , 95, 1143-61  |     | 52  |
| 260 | Antimicrobial therapy of sepsis and septic shock--when are two drugs better than one?. <b>2011</b> , 27, e1-27   |     | 13  |
| 259 | Pneumonia due to <i>Pseudomonas aeruginosa</i> : part I: epidemiology, clinical diagnosis, and source. <i>Chest</i> , <b>2011</b> , 139, 909-919   | 5.3 | 159 |
| 258 | Management of community-acquired pneumonia in adults. <b>2011</b> , 183, 157-64  |     | 69  |
| 257 | Incidence of cardiovascular events after hospital admission for pneumonia. <b>2011</b> , 124, 244-51   |     | 71  |
| 256 | [The short stay unit as an alternative to conventional hospitalisation in the treatment of community acquired pneumonia in the over 75 year-old population]. <b>2011</b> , 46, 213-6   |     | 3   |
| 255 | Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. <b>2011</b> , 28, 122-7   |     | 37  |
| 254 | Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. <b>2011</b> , 15, R96   |     | 84  |
| 253 | Only severely limited, premorbid functional status is associated with short- and long-term mortality in patients with pneumonia who are critically ill: a prospective observational study. <i>Chest</i> , <b>2011</b> , 139, 88-94 | 5.3 | 41  |
| 252 | Infections respiratoires basses de l'adulte. <b>2011</b> , 8, 1-20   |     |     |
| 251 | Plasma neutrophil elastase correlates with pulmonary vascular permeability: a prospective observational study in patients with pneumonia. <b>2011</b> , 16, 953-8  |     | 20  |
| 250 | Smoking and the outcome of infection. <b>2011</b> , 269, 258-69  |     | 97  |
| 249 | Tissue factor pathway inhibitor and bacterial infection. <b>2011</b> , 9, 119-21   |     | 4   |

|     |  |          |
|-----|--|----------|
| 248 | Alcohol intoxication/dependence, ethnicity and utilisation of health care resources in a level I trauma center. <b>2011</b> , 42, 66-71  | 13       |
| 247 | Diabetes is not associated with increased mortality in emergency department patients with sepsis. <b>2011</b> , 58, 438-44   | 34       |
| 246 | Association between the number of blood cultures and appropriateness of care for suspected bacteremic urinary tract infection in the elderly. <b>2011</b> , 17, 341-50                             | 2        |
| 245 | Early rise in circulating endothelial protein C receptor correlates with poor outcome in severe sepsis. <b>2011</b> , 37, 950-6  | 17       |
| 244 | Infections communautaires graves – Les pneumonies aiguës communautaires bactériennes de l'adulte. <b>2011</b> , 20, 566-575  | 0        |
| 243 | CURB-65 and SMART-CO in the prediction of early transfers to the intensive care unit among patients with community-acquired pneumonia initially admitted to a general ward. <b>2011</b> , 6, 513-8 | 3        |
| 242 | Diagnostic tests for agents of community-acquired pneumonia. <b>2011</b> , 52 Suppl 4, S296-304  | 156      |
| 241 | Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. <b>2011</b> , 37, 393-9  | 54       |
| 240 | Primary Care Management of Community-Acquired Pneumonia. <b>2011</b> ,   |          |
| 239 | Prognostic value of serum angiotensin-converting enzyme activity for outcome of community-acquired pneumonia. <b>2011</b> , 49, 1525-32  | 8        |
| 238 | Circulating endothelial cell protein C receptor: endothelial regulation and cumulative impact of gender and A3 haplotype. <b>2011</b> , 48, 336-46   | 10       |
| 237 | Diabetes and sepsis: preclinical findings and clinical relevance. <b>2011</b> , 34, 771-8  | 93       |
| 236 | Which Pneumonia Severity Scoring System is the Best?. <b>2011</b> , 7, 232-245   |          |
| 235 | Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. <i>PLoS Medicine</i> , <b>2011</b> , 8, e1001048              | 11.6 143 |
| 234 | Community-acquired pneumonia: genomics, epigenomics, transcriptomics, proteomics, and metabolomics. <b>2012</b> , 33, 257-65   | 6        |
| 233 | Microbiology and risk factors for community-acquired pneumonia. <b>2012</b> , 33, 220-31   | 37       |
| 232 | Factors associated with hospital mortality in community-acquired legionellosis in France. <b>2012</b> , 39, 963-70   | 32       |
| 231 | Antibiotics Before Hospitalization for CAP. <b>2012</b> , 19, 109-112  |          |

|     |  |    |
|-----|--|----|
| 230 | The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ. <b>2012</b> , 66, 470-5  | 49 |
| 229 | Community-acquired pneumonia guidelines: a global perspective. <b>2012</b> , 33, 298-310   | 35 |
| 228 | Is community-acquired pneumonia an independent risk factor for cardiovascular disease?. <b>2012</b> , 39, 187-96   | 39 |
| 227 | Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. <b>2012</b> , 29, S27-62                           | 71 |
| 226 | Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. <b>2012</b> , 7, e47926   | 73 |
| 225 | Successful treatment of a previously healthy woman with <i>Pseudomonas aeruginosa</i> community-acquired pneumonia with plasmapheresis. <b>2012</b> , 51, 2809-12                      | 11 |
| 224 | Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. <b>2012</b> , 16, R53  | 45 |
| 223 | The remaining challenges of pneumococcal disease in adults. <b>2012</b> , 21, 57-65  | 56 |
| 222 | Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers. <b>2012</b> , 5, 445-58  | 11 |
| 221 | The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia. <b>2012</b> , 42, 133-8  | 11 |
| 220 | D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. <b>2012</b> , 23, 436-41 | 59 |
| 219 | Severe sepsis in community-acquired pneumonia--early recognition and treatment. <b>2012</b> , 23, 412-9  | 19 |
| 218 | Comparative transcriptomic analysis of streptococcus pseudopneumoniae with viridans group streptococci. <b>2012</b> , 12, 77   | 4  |
| 217 | Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012. <b>2012</b> , 44, 885-902                 | 46 |
| 216 | High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. <b>2012</b> , 47, 509-16   | 51 |
| 215 | Eficacia y seguridad de la fisioterapia respiratoria en pacientes adultos con neumonía adquirida en la comunidad. <b>2012</b> , 28, 189-198  |    |
| 214 | Chronic-alcohol-abuse-induced oxidative stress in the development of acute respiratory distress syndrome. <b>2012</b> , 2012, 740308   | 34 |
| 213 | Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. <b>2012</b> , 28, 370-5   | 36 |

|     |  |     |
|-----|--|-----|
| 212 | Impaired inflammatory responses to multiple toll-like receptor ligands in alveolar macrophages of streptozotocin-induced diabetic mice. <b>2012</b> , 61, 417-26   | 8   |
| 211 | The impact of diabetes on the pathogenesis of sepsis. <b>2012</b> , 31, 379-88   | 125 |
| 210 | Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU. <b>2012</b> , 18, 324-31  | 5   |
| 209 | Treatment with anti-inflammatory drugs in community-acquired pneumonia. <b>2012</b> , 272, 25-35   | 24  |
| 208 | Risk factors for the development of acute lung injury in patients with infectious pneumonia. <b>2012</b> , 16, R46   | 29  |
| 207 | Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. <b>2012</b> , 31, 33-47   | 28  |
| 206 | Etiological analysis and predictive diagnostic model building of community-acquired pneumonia in adult outpatients in Beijing, China. <b>2013</b> , 13, 309  | 22  |
| 205 | Impact of positive chest X-ray findings and blood cultures on adverse outcomes following hospitalized pneumococcal lower respiratory tract infection: a population-based cohort study. <b>2013</b> , 13, 197   | 4   |
| 204 | Usefulness of gram-stained sputum obtained just after administration of antimicrobial agents as the earliest therapeutic indicator for evaluating the effectiveness of empiric therapy in community-acquired pneumonia caused by pneumococcus or Moraxella catarrhalis. <b>2013</b> , 19, 517-23 | 2   |
| 203 | Outcomes in females hospitalised with community-acquired pneumonia are worse than in males. <b>2013</b> , 41, 1135-40  | 14  |
| 202 | Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. <b>2013</b> , 107, 1101-11   | 49  |
| 201 | Fatal community-acquired pneumonia: 18 years in a medical center. <b>2013</b> , 54, 22-7   | 13  |
| 200 | Recomendaciones para el diagnóstico, tratamiento y prevención de la neumonía adquirida en la comunidad en adultos inmunocompetentes. <b>2013</b> , 17, 1-38  | 13  |
| 199 | Community-acquired pneumonia in patients with chronic obstructive pulmonary disease requiring admission to the intensive care unit: risk factors for mortality. <b>2013</b> , 28, 975-9  | 21  |
| 198 | Trait sur la maladie d'Alzheimer. <b>2013</b> ,  |     |
| 197 | Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. <b>2013</b> , 10, 81-9  | 164 |
| 196 | [Epidemiology of community-acquired pneumonia]. <b>2013</b> , 45, 503-13   | 3   |
| 195 | Evaluation of B-type natriuretic peptide in patients with community acquired pneumonia. <b>2013</b> , 62, 293-300  | 2   |

|     |  |    |
|-----|--|----|
| 194 | [The elderly with pneumonia, a serious disease of the past and present]. <b>2013</b> , 48, 204-5   |    |
| 193 | Bacterial volatiles and diagnosis of respiratory infections. <b>2013</b> , 82, 29-52   | 12 |
| 192 | Severe community-acquired pneumonia. <b>2013</b> , 29, 563-601   | 47 |
| 191 | C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness. <b>2013</b> , 31, 137-44   | 49 |
| 190 | Epidemiology of patients hospitalised for pneumonia in 2011: a prospective multicentre cohort study. <b>2013</b> , 125, 621-8  | 1  |
| 189 | Pulmonary function tests in type 2 diabetics and non-diabetic people -a comparative study. <b>2013</b> , 7, 1606-8   | 8  |
| 188 | Advances in antibiotic therapy for community-acquired pneumonia. <b>2013</b> , 19, 209-15  | 14 |
| 187 | Do corticosteroids improve outcome for any critical illness?. <b>2013</b> , 26, 164-70   | 7  |
| 186 | The changing microbiologic epidemiology of community-acquired pneumonia. <b>2013</b> , 125, 31-42  | 24 |
| 185 | Simultaneous detection of <i>Streptococcus pneumoniae</i> , <i>S. mitis</i> , and <i>S. oralis</i> by a novel multiplex PCR assay targeting the <i>gyrB</i> gene. <b>2013</b> , 51, 835-40 | 11 |
| 184 | Computers and the diagnosis of pneumonia. <b>2013</b> , 173, 701-2   | 2  |
| 183 | Positive blood culture is not associated with increased mortality in patients with sepsis-induced acute respiratory distress syndrome. <b>2013</b> , 18, 1210-6                            | 10 |
| 182 | Severe community-acquired pneumonia treated with $\beta$ -lactam-respiratory quinolone vs. $\beta$ -lactam-macrolide combination. <b>2013</b> , 57, 587-93                                 | 9  |
| 181 | Prognostic value of plasma N-terminal pro B-type natriuretic peptide levels in pneumonia patients requiring intensive care unit admission. <b>2013</b> , 18, 933-41                        | 8  |
| 180 | Inhaled corticosteroids and the increased risk of pneumonia. <b>2013</b> , 7, 225-34   | 8  |
| 179 | Relationship between severity of adult community-acquired pneumonia and impairment of the antioxidant defense system. <b>2013</b> , 46, 207-13   | 11 |
| 178 | Economic burden and epidemiology of pneumonia in Korean adults aged over 50 years. <b>2013</b> , 28, 888-95  | 25 |
| 177 | FASTCAP study on the management of hospitalized patients with community-acquired pneumonia: pharmaco-economic analysis of the prospective phase. <b>2013</b> , 55-66                       |    |

|     |   |     |     |
|-----|---|-----|-----|
| 176 | [Long-term survival of immunocompetent patients older than 60 years hospitalized for community-acquired pneumonia]. <b>2013</b> , 141, 831-43   |     | 1   |
| 175 | [Predictors of one year mortality among immunocompetent adults hospitalized for community-acquired pneumonia]. <b>2013</b> , 141, 143-52  |     | 0   |
| 174 | Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. <b>2013</b> , 8, e60273   |     | 250 |
| 173 | Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. <b>2013</b> , 45, 351-66   |     | 63  |
| 172 | Guidelines and management of hospitalized patients with community-acquired pneumonia: the Italian experience of the FASTCAP study. <b>2013</b> , 5-18   |     | 0   |
| 171 | Clinical Diagnosis and Severity Assessment in Immunocompetent Adult Patients with Community-Acquired Pneumonia. <b>2013</b> ,   |     |     |
| 170 | Effectiveness of Proadrenomedullin Enhanced CURB65 Score Algorithm in Patients with Community-Acquired Pneumonia in "Real Life", an Observational Quality Control Survey. <i>Journal of Clinical Medicine</i> , <b>2014</b> , 3, 267-79 | 5.1 | 4   |
| 169 | Community-acquired pneumonia caused by carbapenem-resistant <i>Streptococcus pneumoniae</i> : re-examining its prevention and treatment. <b>2014</b> , 7, 253-7   |     | 1   |
| 168 | Pneumococcal Infections: Therapeutic Strategies and Pitfalls. <b>2014</b> , 314-330   |     | 1   |
| 167 | Clinical Relevance of Antibiotic Resistance in Pneumococcal Infections. <b>2014</b> , 331-338   |     |     |
| 166 | Treatment of Community-Acquired Respiratory Tract Infections. <b>2014</b> , 227-243   |     |     |
| 165 | Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia. <b>2014</b> , 1, e000038  |     | 22  |
| 164 | Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential. <b>2014</b> , 21, 1541-9        |     | 11  |
| 163 | Alcohol induced mitochondrial oxidative stress and alveolar macrophage dysfunction. <b>2014</b> , 2014, 371593  |     | 39  |
| 162 | Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). <i>Chest</i> , <b>2014</b> , 146, 22-31   | 5.3 | 56  |
| 161 | Evaluaci3n y manejo de la neumon3a del adulto adquirida en la comunidad. <b>2014</b> , 25, 553-564  |     |     |
| 160 | Community-acquired lobar pneumonia caused by <i>Pseudomonas aeruginosa</i> infection in Japan: a case report with histological and immunohistochemical examination. <b>2014</b> , 64, 224-30  |     | 7   |
| 159 | Pneumococcal infection in adults: burden of disease. <i>Clinical Microbiology and Infection</i> , <b>2014</b> , 20 Suppl 5, 45-51   | 9.5 | 182 |

|     |   |      |    |
|-----|---|------|----|
| 158 | Infection hospitalization increases risk of dementia in the elderly. <b>2014</b> , 42, 1037-46  |      | 41 |
| 157 | Reduction of mortality in community-acquired pneumonia after implementing standardized care bundles in the emergency department. <b>2014</b> , 21, 429-35   |      | 22 |
| 156 | Patient Outcomes on Day 4 of Intravenous Antibiotic Therapy in Non-Intensive Care Unit Hospitalized Adults With Community-Acquired Bacterial Pneumonia. <b>2014</b> , 22, 320-325   |      | 3  |
| 155 | [Reasons for adult immunization -- prevention of most frequent respiratory infections]. <b>2014</b> , 155, 1743-7   |      | 0  |
| 154 | Respiratory infections. <b>2014</b> , 161, 203-36   |      | 4  |
| 153 | [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults]. <b>2014</b> , 155, 1996-2004  |      | 4  |
| 152 | Vaccination anti-pneumococcique chez lâädulte : comment améliorer la couverture vaccinale ?. <b>2014</b> , 16, 89-98  |      | 1  |
| 151 | Infectious Complications in Cancer Patients. <b>2014</b> ,  |      | 4  |
| 150 | A benefit-risk assessment of the use of proton pump inhibitors in the elderly. <b>2014</b> , 31, 263-82   |      | 29 |
| 149 | Bacteremia prediction model using a common clinical test in patients with community-acquired pneumonia. <b>2014</b> , 32, 700-4   |      | 21 |
| 148 | Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. <i>Journal of Infection</i> , <b>2014</b> , 68, 534-41  | 18.9 | 25 |
| 147 | Retrospective analysis of nursing and healthcare-associated pneumonia: analysis of adverse prognostic factors and validity of the selection criteria. <b>2014</b> , 52, 114-20  |      | 12 |
| 146 | Infecciones por neumococo. <b>2014</b> , 11, 3485-3492  |      |    |
| 145 | Pneumococcal pneumonia: differences according to blood culture results. <i>BMC Pulmonary Medicine</i> , <b>2014</b> , 14, 128   | 3.5  | 16 |
| 144 | [Pneumonia with an unusual outcome and with no clinical-radiological association]. <b>2014</b> , 40, 159-62   |      | 0  |
| 143 | Community-Acquired Pneumonia Among Smokers. <b>2014</b> , 50, 250-254   |      | 3  |
| 142 | Assessing the burden of diabetes mellitus in emergency departments in the United States: the National Hospital Ambulatory Medical Care Survey (NHAMCS). <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 639-45 | 3.2  | 5  |
| 141 | Community-acquired pneumonia among smokers. <b>2014</b> , 50, 250-4   |      | 24 |



|     |  |     |    |
|-----|--|-----|----|
| 140 | [Severe community-acquired pneumonia admitted at the intensive care unit: main clinical and bacteriological features and prognostic factors: a Tunisian experience]. <b>2014</b> , 70, 253-9 |     | 4  |
| 139 | Antibacterial activities of acetonides prepared from the seed oils of <i>Calophyllum inophyllum</i> and <i>Pterocarpus osun</i> . <b>2014</b> , 4, 75-80                                     |     | 6  |
| 138 | Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore. <b>2014</b> , 7, 179-91  |     | 8  |
| 137 | Studying the burden of community-acquired pneumonia in adults aged ≥50 years in primary health care: an observational study in rural Crete, Greece. <b>2014</b> , 24, 14017                  |     | 11 |
| 136 | Respiratory Intensive Care. <b>2014</b> , 551-593  |     |    |
| 135 | Tobacco smoking increases the risk for death from pneumococcal pneumonia. <i>Chest</i> , <b>2014</b> , 146, 1029-1033  |     | 53 |
| 134 | Importance of <i>Legionella pneumophila</i> in the etiology of severe community-acquired pneumonia in Santiago, Chile. <i>Chest</i> , <b>2014</b> , 145, 290-296                             | 5.3 | 20 |
| 133 | Association between diabetes and increased prevalence of paranasal sinus disease: a cross-sectional study in Japanese adults. <b>2015</b> , 25, 297-302                                      |     | 5  |
| 132 | Glucose Homeostasis and Cardiovascular Alterations in Diabetes. <b>2015</b> , 5, 1815-39   |     | 12 |
| 131 | Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. <b>2015</b> , 16, 89-97   |     | 52 |
| 130 | Etiological Diagnosis of Community-Acquired Pneumonia in Adult Patients: A Prospective Hospital-Based Study in Mashhad, Iran. <b>2015</b> , 8, e22780  |     | 9  |
| 129 | [Clinical predictors of bacteremia in immunocompetent adult patients hospitalized for community-acquired pneumonia]. <b>2015</b> , 143, 553-61   |     | 2  |
| 128 | Acute Pneumonia. <b>2015</b> , 823-846.e5  |     | 8  |
| 127 | Risk factors and antibiotic therapy in <i>P. aeruginosa</i> community-acquired pneumonia. <b>2015</b> , 20, 660-6  |     | 23 |
| 126 | The irregular diaphragmatic pleural interface: a novel sonographic sign facilitating the diagnosis of pneumonia. <b>2015</b> , 34, 1147-57   |     | 1  |
| 125 | Estimated hospitalization rate for diseases attributable to <i>Streptococcus pneumoniae</i> in the Veneto region of north-east Italy. <b>2015</b> , 2, 27-31                                 |     | 1  |
| 124 | Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. <b>2015</b> , 17, 379-85  |     | 13 |
| 123 | Molecular epidemiological characteristics of <i>Klebsiella pneumoniae</i> associated with bacteremia among patients with pneumonia. <b>2015</b> , 53, 879-86                                 |     | 26 |

|     |  |      |     |
|-----|--|------|-----|
| 122 | Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 677-86 | 27.4 | 306 |
| 121 | Diabetes mellitus increases severity of thrombocytopenia in dengue-infected patients. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 3820-30   | 6.3  | 15  |
| 120 | Excess Risk of Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes. <b>2015</b> , 38, 1274-80  |      | 41  |
| 119 | Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. <b>2015</b> , 43, 699-706  |      | 11  |
| 118 | A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools. <b>2015</b> , 22, 785-99   |      | 25  |
| 117 | Lysophosphatidylcholine as a prognostic marker in community-acquired pneumonia requiring hospitalization: a pilot study. <b>2015</b> , 34, 309-15  |      | 12  |
| 116 | Pneumonie âThe old manâ friendâ <b>2015</b> , 12, 134-139  |      | 0   |
| 115 | Cardiovascular Complications in Community-acquired Pneumonia. <b>2015</b> , 22, 62-67  |      | 2   |
| 114 | Epidemiology, etiology, and risk factors of bacterial pneumonia. <b>2015</b> , 7-28  |      | 1   |
| 113 | Pneumonies aiguës communautaires: peut-on encore en améliorer le pronostic?. <b>2015</b> , 7, 227-237  |      |     |
| 112 | Clinical Management of Bacterial Pneumonia. <b>2015</b> ,  |      | 7   |
| 111 | Biomarkers in community-acquired pneumonia. <i>Journal of Infection</i> , <b>2015</b> , 71, 695-6  | 18.9 | 4   |
| 110 | The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. <b>2015</b> , 5, e006251  |      | 36  |
| 109 | Avian influenza and live mixed poultry-animal markets in China. <i>Journal of Infection</i> , <b>2015</b> , 71, 693-5  | 18.9 | 0   |
| 108 | Severe community-acquired pneumonia and positive urinary antigen test for <i>S. pneumoniae</i> : amoxicillin is associated with a favourable outcome. <b>2015</b> , 34, 2455-61  |      | 12  |
| 107 | Is there a potential role for echocardiography in adult patients with CAP?. <b>2015</b> , 33, 1672-6   |      | 16  |
| 106 | Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. <b>2015</b> , 45, 463-72  |      | 64  |
| 105 | Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins. <b>2015</b> , 34, 511-8   |      | 11  |


|     |  |     |     |
|-----|--|-----|-----|
| 104 | Prognostic value of on admission arterial PCO in hospitalized patients with community-acquired pneumonia. <b>2016</b> , 8, 2765-2771   |     | 3   |
| 103 | Fatty acid-binding proteins as diagnostic and prognostic markers in pneumonia. <b>2016</b> , 4, 495  |     |     |
| 102 | Computed Tomography for the Diagnosis and Evaluation of the Severity of Community-acquired Pneumonia in the Elderly. <b>2016</b> , 55, 437-41  |     | 18  |
| 101 | Association of Diabetes and Insulin Therapy With Risk of Hospitalization for Infection and 28-Day Mortality Risk. <b>2017</b> , 64, 435-442  |     | 12  |
| 100 | Blood Lactate Levels Cutoff and Mortality Prediction in Sepsis-Time for a Reappraisal? a Retrospective Cohort Study. <b>2016</b> , 46, 480-485   |     | 61  |
| 99  | Prediction of clinical outcomes in community-acquired pneumonia. <b>2016</b> , 65, 167   |     |     |
| 98  | A minimum blood glucose value less than or equal to 120 mg/dL under glycemic control is associated with increased 14-day mortality in nondiabetic intensive care unit patients with sepsis and stress hyperglycemia. <b>2016</b> , 34, 69-73 |     | 12  |
| 97  | Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia. <i>Chest</i> , <b>2016</b> , 150, 819-828  | 5-3 | 26  |
| 96  | Neumonía aguda extrahospitalaria. <b>2016</b> , 20, 1-10   |     |     |
| 95  | Predictors of in-hospital mortality and length of stay in community-acquired pneumonia: a 5-year multi-centre case control study of adults in a developing country. <b>2016</b> , 110, 445-55  |     | 8   |
| 94  | Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients. <b>2016</b> , 59, 2552-2560  |     | 12  |
| 93  | Risk factors for mortality in patients admitted to intensive care units with pneumonia. <b>2016</b> , 17, 80   |     | 23  |
| 92  | Predictive factors of true bacteremia and the clinical utility of blood cultures as a prognostic tool in patients with community-onset pneumonia. <b>2016</b> , 95, e5058  |     | 8   |
| 91  | Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?. <b>2016</b> , 22, 308-314  |     | 11  |
| 90  | Composition and dynamics of the respiratory tract microbiome in intubated patients. <b>2016</b> , 4, 7   |     | 100 |
| 89  | Respiratory Infections. <b>2016</b> ,  |     | 1   |
| 88  | Precision medicine for the treatment of severe pneumonia in intensive care. <b>2016</b> , 10, 297-316  |     | 20  |
| 87  | Risk factors for mortality despite early protocolized resuscitation for severe sepsis and septic shock in the emergency department. <b>2016</b> , 31, 13-20  |     | 24  |

|    |  |         |
|----|--|---------|
| 86 | Impact of hyperglycemia on outcomes of patients with <i>Pseudomonas aeruginosa</i> bacteremia. <b>2016</b> , 84, 155-8   | 4       |
| 85 | Whole-Genome Sequencing Reveals the Origin and Rapid Evolution of an Emerging Outbreak Strain of <i>Streptococcus pneumoniae</i> 12F. <b>2016</b> , 62, 1126-1132                                      | 22      |
| 84 | Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia: A Nationwide Population-Based Cohort Study. <b>2016</b> , 95, e2763 | 4       |
| 83 | Are Pathogenic <i>Leptospira</i> Species Agents of Community-Acquired Pneumonia? Case Reports of Leptospirosis Presenting as Pneumonia. <b>2016</b> , 54, 197-9  | 4       |
| 82 | Community Acquired Pneumonia. 149-152  |         |
| 81 | Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens. <b>2017</b> , 2,  | 19      |
| 80 | Tools for outcome prediction in patients with community acquired pneumonia. <b>2017</b> , 10, 201-211  | 16      |
| 79 | Emergence of Antimicrobial Resistance among <i>Pseudomonas aeruginosa</i> : Implications for Therapy. <b>2017</b> , 38, 326-345  | 21      |
| 78 | Bacterial Pneumonia in Older Adults. <b>2017</b> , 31, 689-713   | 43      |
| 77 | Bacteremia Prediction Model for Community-acquired Pneumonia: External Validation in a Multicenter Retrospective Cohort. <b>2017</b> , 24, 1226-1234   | 11      |
| 76 | Diabetes Is Not Associated With Increased 90-Day Mortality Risk in Critically Ill Patients With Sepsis. <b>2017</b> , 45, e1026-e1035  | 27      |
| 75 | Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. <b>2017</b> , 65, 2091-2098   | 16      |
| 74 | Predictores clínicos de eventos adversos serios en el adulto inmunocompetente hospitalizado por neumonía adquirida en la comunidad. <b>2017</b> , 33, 99-112   |         |
| 73 | Weather-Dependent Risk for Legionnaires' Disease, United States. <i>Emerging Infectious Diseases</i> , <b>2017</b> , 23, 1843-1851   | 10.2 31 |
| 72 | Management of community acquired pneumonia by Family Physicians. <b>2017</b> , 33, 783-787   | 1       |
| 71 | Can N-terminal pro B-type natriuretic peptide, neutrophil-to-lymphocyte ratio, C-reactive protein help to predict short and long term mortality?. <b>2016</b> , 117, 587-594                           | 2       |
| 70 | [Adverse event prediction in immunocompetent adult patients hospitalized with community-acquired pneumonia]. <b>2017</b> , 145, 694-702  |         |
| 69 | Clinical Presentation and Bacterial Etiology of Adult Community Acquired Pneumonia. <b>2017</b> , 34, 128-134  |         |

|    |   |    |
|----|---|----|
| 68 | South African guideline for the management of community-acquired pneumonia in adults. <b>2017</b> , 9, 1469-1502  | 33 |
| 67 | Solithromycin for community acquired pneumonia in adults. <b>2017</b> , 1, 1-1  |    |
| 66 | Long-term Mortality in Community-acquired Pneumonia. <b>2018</b> , 54, 412-413  | 4  |
| 65 | Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. <b>2018</b> , 40, 34-38  | 16 |
| 64 | The Effect of Preoperative Pneumonia on Postsurgical Mortality and Morbidity: A NSQIP Analysis. <b>2018</b> , 42, 2763-2772   | 10 |
| 63 | Acute cardiac events in severe community-acquired pneumonia: A multicenter study. <b>2018</b> , 12, 2212-2219   | 20 |
| 62 | Prediction model for mortality in cancer patients with pneumonia: comparison with CURB-65 and PSI. <b>2018</b> , 12, 538-546  | 6  |
| 61 | Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study. <b>2018</b> , 43, 183-189   | 22 |
| 60 | Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. <b>2018</b> , 50, 247-272  | 18 |
| 59 | Sepsis and community-acquired pneumonia. <b>2018</b> , 2, 7-7   | 8  |
| 58 | Prognostic factors for mortality due to pneumonia among adults from different age groups in Singapore and mortality predictions based on PSI and CURB-65. <b>2018</b> , 59, 190-198 | 28 |
| 57 | Early, short and long-term mortality in community-acquired pneumonia. <b>2018</b> , 2, 5-5  | 6  |
| 56 | Cost-Utility Study of PCV13 Versus PPSV23 in Adults in Chile. <b>2018</b> , 17, 194-201   | 3  |
| 55 | Neumonías adquiridas en la comunidad. <b>2018</b> , 12, 3751-3762   |    |
| 54 | Acute Infectious Diseases and the Athlete. <b>2018</b> , 250-258  |    |
| 53 | Relative Clinical and Cost Burden of Community-Acquired Pneumonia Hospitalizations in Older Adults in the United States-A Cross-Sectional Analysis. <b>2018</b> , 6,                | 12 |
| 52 | Evaluation of the Quality of Care among Hospitalized Adult Patients with Community-Acquired Pneumonia in Korea. <b>2018</b> , 81, 175-186   | 2  |
| 51 | Risk Factors for Death From Psychiatric Hospital-acquired Pneumonia. <b>2018</b> , 57, 2473-2478  | 5  |

|    |   |      |    |
|----|---|------|----|
| 50 | Prognostic value of pneumococcal urinary antigen test in community-acquired pneumonia. <b>2018</b> , 13, e0200620   |      | 4  |
| 49 | Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. <b>2018</b> , 81, 187-197   |      | 46 |
| 48 | Impact of Postoperative Pneumonia Developing After Discharge on Long-Term Follow-up for Resected Lung Cancer. <b>2018</b> , 42, 3979-3987   |      | 9  |
| 47 | Long-term Mortality in Community-acquired Pneumonia. <b>2018</b> , 54, 412-413  |      | 0  |
| 46 | Streptococcus pneumoniae Sialidase SpNanB-Catalyzed One-Pot Multienzyme (OPME) Synthesis of 2,7-Anhydro-Sialic Acids as Selective Sialidase Inhibitors. <b>2018</b> , 83, 10798-10804                     |      | 12 |
| 45 | Predicting 1-year mortality after hospitalization for community-acquired pneumonia. <b>2018</b> , 13, e0192750  |      | 10 |
| 44 | Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. <b>2018</b> , 13, e0197418                                  |      | 12 |
| 43 | Intra-hospital mortality for community-acquired pneumonia in mainland Portugal between 2000 and 2009. <b>2019</b> , 25, 66-70   |      | 7  |
| 42 | The change in age distribution of CAP population in Korea with an estimation of clinical implications of increasing age threshold of current CURB65 and CRB65 scoring system. <b>2019</b> , 14, e0219367  |      | 1  |
| 41 | Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. <i>BMC Pulmonary Medicine</i> , <b>2019</b> , 19, 179                                  | 3.5  | 15 |
| 40 | Factors influencing long-term survival after hospitalization with pneumococcal pneumonia. <i>Journal of Infection</i> , <b>2019</b> , 79, 542-549   | 18.9 | 3  |
| 39 | Adult Vaccinations. <i>Practical Issues in Geriatrics</i> , <b>2019</b> ,   | 0.1  | 1  |
| 38 | Impact of Lymphocyte and Neutrophil Counts on Mortality Risk in Severe Community-Acquired Pneumonia with or without Septic Shock. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,                  | 5.1  | 13 |
| 37 | Reduced risk of stroke among psychiatric patients receiving ECT: A population-based cohort study in Taiwan. <i>Psychiatry Research</i> , <b>2019</b> , 276, 107-111                                       | 9.9  | 2  |
| 36 | Biomarkers in Pneumonia-Beyond Procalcitonin. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,  | 6.3  | 35 |
| 35 | Community-acquired Pneumonia and Hospital-acquired Pneumonia. <i>Medical Clinics of North America</i> , <b>2019</b> , 103, 487-501  | 7    | 67 |
| 34 | Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1237  | 5.6  | 2  |
| 33 | Ambient particulate matter pollution and adult hospital admissions for pneumonia in urban China: A national time series analysis for 2014 through 2017. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1003010 | 11.6 | 48 |

|    |  |      |    |
|----|--|------|----|
| 32 | Usefulness of Early C-Reactive Protein Kinetics in Response and Prognostic Assessment in Infected Critically Ill Patients: An Observational Retrospective Study. <i>Acta Medica Portuguesa</i> , <b>2019</b> , 32, 737-745                 | 1.4  | 2  |
| 31 | GM-CSF Administration Improves Defects in Innate Immunity and Sepsis Survival in Obese Diabetic Mice. <i>Journal of Immunology</i> , <b>2019</b> , 202, 931-942  | 5.3  | 11 |
| 30 | The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia. <i>Chest</i> , <b>2019</b> , 155, 787-794   | 5.3  | 6  |
| 29 | Urinary antigen testing in community-acquired pneumonia in adults: an update. <i>Expert Review of Anti-Infective Therapy</i> , <b>2019</b> , 17, 107-115   | 5.5  | 13 |
| 28 | Self-reported alcohol use in the cystic fibrosis community. <i>Journal of Cystic Fibrosis</i> , <b>2020</b> , 19, 84-90  | 4.1  | 3  |
| 27 | Optimal specimen type for accurate diagnosis of infectious peripheral pulmonary lesions by mNGS. <i>BMC Pulmonary Medicine</i> , <b>2020</b> , 20, 268   | 3.5  | 7  |
| 26 | Prognostic value of chest computed tomography in community-acquired pneumonia patients. <i>ERJ Open Research</i> , <b>2020</b> , 6,  | 3.5  | 1  |
| 25 | Factors Associated with Treatment Failure in Patients with Acute Exacerbation of COPD Admitted to the Emergency Department Observation Unit. <i>Emergency Medicine International</i> , <b>2020</b> , 2020, 8261375 <sup>1.4</sup>          | 1.4  | 1  |
| 24 | Kortikosteroidi kod teže pneumonije. <i>Infektološki Glasnik</i> , <b>2020</b> , 39, 119-123   | 0.1  |    |
| 23 | Deaths Associated with Pneumonic Plague, 1946-2017. <i>Emerging Infectious Diseases</i> , <b>2020</b> , 26, 2432-2434 <sup>0.2</sup>   | 0.2  | 3  |
| 22 | Cold agglutinin disease following SARS-CoV-2 and co-infections. <i>Clinical Case Reports (discontinued)</i> , <b>2020</b> , 8, 2402  | 0.7  | 7  |
| 21 | Dynamics of the lung microbiome in intensive care patients with chronic obstructive pulmonary disease and community-acquired pneumonia. <i>Scientific Reports</i> , <b>2020</b> , 10, 11046  | 4.9  | 5  |
| 20 | The impact of ambient ozone pollution on pneumonia: A nationwide time-series analysis. <i>Environment International</i> , <b>2020</b> , 136, 105498  | 12.9 | 24 |
| 19 | Gender differences in incidence and in-hospital outcomes of community-acquired, ventilator-associated and nonventilator hospital-acquired pneumonia in Spain. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13762 | 2.9  | 2  |
| 18 | Diabetes on sepsis outcomes in non-ICU patients: A cohort study and review of the literature. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107765  | 3.2  | 2  |
| 17 | Mixed bacteremic pneumonia by <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> . <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 571-571  | 9.5  | 1  |
| 16 | Mixed bacteremic pneumonia by <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> . <i>Clinical Microbiology and Infection</i> , <b>2001</b> , 7, 571-571  | 9.5  | 1  |
| 15 | BgaA acts as an adhesin to mediate attachment of some pneumococcal strains to human epithelial cells. <i>Microbiology (United Kingdom)</i> , <b>2011</b> , 157, 2369-2381  | 2.9  | 35 |

|    |   |     |   |
|----|---|-----|---|
| 14 | Current Concepts of Severe Pneumococcal Community-acquired Pneumonia. <i>Yearbook of Intensive Care and Emergency Medicine</i> , <b>2007</b> , 133-144  |     |   |
| 13 | Community-Acquired Respiratory Complications in the Intensive Care Unit: Pneumonia and Acute Exacerbations of COPD. <b>2007</b> , 435-448   |     |   |
| 12 | Current Concepts of Severe Pneumococcal Community-acquired Pneumonia. <b>2007</b> , 33, 133-144   |     | 7 |
| 11 | A case of thoracic empyema with serious COPD successfully treated by thoracoscopic decortication. <i>The Journal of the Japanese Association for Chest Surgery</i> , <b>2008</b> , 22, 805-809            | 0   |   |
| 10 | Retrospective analysis of management of inpatient adults with community-acquired pneumonia (findings of medical reports). <i>Pulmonologiya</i> , <b>2009</b> , 44-50                                      | 0.8 |   |
| 9  |  <i>Pulmonologiya</i> , <b>2009</b> , 33-41  | 0.8 |   |
| 8  | A Study on analysis of severity-adjustment length of stay in hospital for community-acquired pneumonia. <i>Journal of the Korea Academia-Industrial Cooperation Society</i> , <b>2011</b> , 12, 1234-1243 |     | 3 |
| 7  | Diagnosis and treatment of community acquired pneumonia - the German perspective. <b>2007</b> , 1-14  |     | 1 |
| 6  | Infections in Diabetes Mellitus. <b>2006</b> , 377-401  |     |   |
| 5  | Federal guidelines on diagnosis and treatment of community-acquired pneumonia. <i>Pulmonologiya</i> , <b>2022</b> , 32, 295-355   | 0.8 | 1 |
| 4  | Gearing up for battle: Harnessing adaptive T cell immunity against gram-negative pneumonia. 12,   |     | 0 |
| 3  | Association Between Empirical Anti-Pseudomonal Antibiotics for Recurrent Lower Respiratory Tract Infections and Mortality: A Retrospective Cohort Study. Volume 17, 2919-2929                             |     | 0 |
| 2  | Thiazolidinediones lower the risk of pneumonia in patients with type 2 diabetes. 14,  |     | 0 |
| 1  | SARS in Singapore âPredictors of Disease Severity. <b>2006</b> , 35, 326-331  |     | 1 |